

CPC COOPERATIVE PATENT CLASSIFICATION

C CHEMISTRY; METALLURGY

(NOTES omitted)

CHEMISTRY

C12 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

(NOTES omitted)

C12N MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ([microbiological testing media C12Q 1/00](#))

NOTES

1. Attention is drawn to Notes (1) to (3) following the title of class [C12](#).
2. Biocidal, pest repellent, pest attractant or plant growth regulatory activity of compounds or preparations is further classified in subclass [A01P](#).
3. Therapeutic activity of single-cell proteins or enzymes is further classified in subclass [A61P](#).
4. When classifying in this subclass, classification is also made in group [B01D 15/08](#) insofar as subject matter of general interest relating to chromatography is concerned.
5. In this subclass, it is desirable to add the indexing codes of subclass [C12R](#).
6. {Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes.}
7. {In this subclass, combination sets [C-Sets] are used. The detailed information about the C-Sets construction and the associated syntax rules is present in the definitions of [C12N](#).}

WARNINGS

1. The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

C12N 1/11	covered by	C12N 15/79
C12N 1/13	covered by	C12N 15/79
C12N 1/15	covered by	C12N 15/80
C12N 1/19	covered by	C12N 15/81
C12N 1/21	covered by	C12N 15/74
C12N 5/02	covered by	C12N 5/0006 , C12N 5/04 - C12N 5/166
C12N 5/07 - C12N 5/095	covered by	C12N 5/06
C12N 5/18	covered by	C12N 5/16
C12N 5/20	covered by	C12N 5/163
C12N 5/22	covered by	C12N 5/16
C12N 5/24	covered by	C12N 5/163
C12N 5/26	covered by	C12N 5/166
C12N 5/28	covered by	C12N 5/166
C12N 15/53	covered by	C12N 9/0004
C12N 7/01	covered by	C12N 7/00
C12N 9/02-C12N 9/08	covered by	C12N 9/0004
C12N 9/26	covered by	C12N 9/2408
C12N 9/28-C12N 9/30	covered by	C12N 9/2414 - C12N 9/242
C12N 9/32	covered by	C12N 9/2422
C12N 9/34	covered by	C12N 9/2428
C12N 9/36	covered by	C12N 9/2462
C12N 9/38	covered by	C12N 9/2468
C12N 9/40	covered by	C12N 9/2465
C12N 9/42	covered by	C12N 9/2434
C12N 9/44	covered by	C12N 9/2451
C12N 9/46	covered by	C12N 9/2454
C12N 9/56	covered by	C12N 9/54
C12N 9/66	covered by	C12N 9/6448
C12N 9/68	covered by	C12N 9/6435
C12N 9/70	covered by	C07K 14/3153
C12N 9/72	covered by	C12N 9/6462

C12N

C12N

(continued)

C12N 9/74	covered by	C12N 9/6429
C12N 9/76	covered by	C12N 9/6427
C12N 15/05	covered by	C12N 5/14
C12N 15/06	covered by	C12N 5/16
C12N 15/07	covered by	C12N 5/16
C12N 15/08	covered by	C12N 5/166
C12N 15/12	covered by	C07K 14/435
C12N 15/13	covered by	C07K 16/00
C12N 15/14	covered by	C07K 14/765
C12N 15/15	covered by	C07K 14/81
C12N 15/16	covered by	C07K 14/575
C12N 15/17	covered by	C07K 14/62
C12N 15/18	covered by	C07K 14/61
C12N 15/19	covered by	C07K 14/52
C12N 15/20	covered by	C07K 14/555
C12N 15/21	covered by	C07K 14/56
C12N 15/22	covered by	C07K 14/565
C12N 15/23	covered by	C07K 14/57
C12N 15/24	covered by	C07K 14/54
C12N 15/25	covered by	C07K 14/545
C12N 15/26	covered by	C07K 14/55
C12N 15/27	covered by	C07K 14/53
C12N 15/28	covered by	C07K 14/525
C12N 15/29	covered by	C07K 14/415
C12N 15/30	covered by	C07K 14/44
C12N 15/31	covered by	C07K 14/195 , C07K 14/005
C12N 15/32	covered by	C07K 14/325
C12N 15/33	covered by	C07K 14/005
C12N 15/34	covered by	C07K 14/01
C12N 15/35	covered by	C07K 14/015
C12N 15/36	covered by	C07K 14/02
C12N 15/37	covered by	C07K 14/025
C12N 15/38	covered by	C07K 14/03
C12N 15/39	covered by	C07K 14/065
C12N 15/40	covered by	C07K 14/08
C12N 15/41	covered by	C07K 14/085
C12N 15/42	covered by	C07K 14/09
C12N 15/43	covered by	C07K 14/105
C12N 15/44	covered by	C07K 14/11
C12N 15/45	covered by	C07K 14/115
C12N 15/46	covered by	C07K 14/14
C12N 15/47	covered by	C07K 14/145
C12N 15/48	covered by	C07K 14/15
C12N 15/49	covered by	C07K 14/155
C12N 15/50	covered by	C07K 14/165
C12N 15/51	covered by	C07K 14/02 , C07K 14/10 , C07K 14/18
C12N 15/53	covered by	C12N 9/0004
C12N 15/54	covered by	C12N 9/10
C12N 15/55	covered by	C12N 9/14
C12N 15/56	covered by	C12N 9/24
C12N 15/57	covered by	C12N 9/48
C12N 15/58	covered by	C12N 9/6456
C12N 15/59	covered by	C12N 9/6483
C12N 15/60	covered by	C12N 9/88
C12N 15/61	covered by	C12N 9/90
C12N 15/83	covered by	C12N 15/82
C12N 15/84	covered by	C12N 15/82

2. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.

1/00 Microorganisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from protozoa, bacteria or viruses [A61K 35/66](#), from algae [A61K 36/02](#), from fungi [A61K 36/06](#); preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, [A61K 39/00](#)); **Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor**

- 1/005 . {after treatment of microbial biomass not covered by [C12N 1/02](#) - [C12N 1/08](#)}
- 1/02 . Separating microorganisms from their culture media
- 1/04 . Preserving or maintaining viable microorganisms (immobilised microorganisms [C12N 11/00](#))
- 1/06 . Lysis of microorganisms
- 1/063 . . {of yeast}
- 1/066 . . {by physical methods}
- 1/08 . Reducing the nucleic acid content
- 1/10 . Protozoa; Culture media therefor
- 1/105 . . {Protozoal isolates}
- 1/12 . Unicellular algae; Culture media therefor (as new plants [A01H 13/00](#))
- 1/125 . . {Unicellular algae isolates}
- 1/14 . Fungi (culture of mushrooms [A01G 18/00](#); as new plants [A01H 15/00](#)); Culture media therefor
- 1/145 . . {Fungal isolates}
- 1/16 . . Yeasts; Culture media therefor
- 1/165 . . . {Yeast isolates}
- 1/18 . . . Baker's yeast; Brewer's yeast
- 1/185 {Saccharomyces isolates}
- 1/20 . Bacteria; Culture media therefor
- 1/205 . . {Bacterial isolates}
- 1/22 . Processes using, or culture media containing, cellulose or hydrolysates thereof
- 1/24 . Processes using, or culture media containing, waste sulfite liquor
- 1/26 . Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms [C10G 32/00](#))
- 1/28 . . aliphatic
- 1/30 . . . having five or less carbon atoms
- 1/32 . Processes using, or culture media containing, lower alkanols, i.e. C₁ to C₆
- 1/34 . Processes using foam culture
- 1/36 . Adaptation or attenuation of cells
- 1/38 . Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound ([C12N 1/34](#) takes precedence)

3/00 Spore forming or isolating processes

5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques [A01H 4/00](#))

NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm,

endoderm), the germ line and extra-embryonic tissues such as the placenta;

- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage;
- "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

- 5/0006 . {Modification of the membrane of cells, e.g. cell decoration}
- 5/0012 . {Cell encapsulation}
- 5/0018 . {Culture media for cell or tissue culture (media for specific animal cell type [C12N 5/06](#))}
- 5/0025 . . {Culture media for plant cell or plant tissue culture}
- 5/0031 . . {Serum-free culture media}

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 5/0037](#) - [C12N 5/0056](#)

- 5/0037 . . {Serum-free medium, which may still contain naturally-sourced components}
- 5/0043 . . {Medium free of human- or animal-derived components}
- 5/005 . . {Protein-free medium}
- 5/0056 . . {Xeno-free medium}
- 5/0062 . {General methods for three-dimensional culture}
- 5/0068 . {General culture methods using substrates (for specific animal cell type [C12N 5/06](#))}
- 5/0075 . . {using microcarriers}
- 5/0081 . {Purging biological preparations of unwanted cells}
- 5/0087 . . {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- 5/0093 . . {Purging against cancer cells}
- 5/04 . Plant cells or tissues {(culture media [C12N 5/0025](#))}
- 5/06 . {Animal cells or tissues; Human cells or tissues (preservation of living cells or tissues [A01N 1/02](#))}

NOTE

{In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage. }

"Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with

C12N

C12N 5/06
(continued)

pluripotent cells. Multipotent cells should not be classified with pluripotent cells. The last place priority rule does not apply between the subgroups of this group

- 5/0601 . . {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- 5/0602 . . {Vertebrate cells}

NOTE

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

- 5/0603 . . . {Embryonic cells (production of embryos, nuclear transfer [A01K 67/027](#)); Embryoid bodies}
- 5/0604 {Whole embryos; Culture medium therefor}
- 5/0605 {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- 5/0606 {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells [C12N 5/0611](#), induced pluripotent stem cells [C12N 5/0696](#))}
- 5/0607 . . . {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells [C12N 5/0696](#))}
- 5/0608 . . . {Germ cells (production of embryos, nuclear transfer [A01K 67/027](#))}
- 5/0609 {Oocytes, oögonia (fertilised oocytes [C12N 5/0604](#))}
- 5/061 {Sperm cells, spermatogonia}
- 5/0611 {Primordial germ cells, e.g. embryonic germ cells [EG]}
- 5/0612 {sorting of gametes, e.g. according to sex or motility}
- 5/0613 . . . {Cells from endocrine organs (pancreas [C12N 5/0676](#), gonads [C12N 5/0681](#))}
- 5/0614 {Adrenal gland}
- 5/0615 {Pineal gland}
- 5/0616 {Pituitary gland}
- 5/0617 {Thyroid and parathyroid glands}
- 5/0618 . . . {Cells of the nervous system}
- 5/0619 {Neurons}
- 5/062 {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- 5/0621 {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors [C12N 5/062](#))}
- 5/0622 {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- 5/0623 {Stem cells}
- 5/0625 . . . {Epidermal cells, skin cells; Cells of the oral mucosa}
- 5/0626 {Melanocytes}
- 5/0627 {Hair cells}
- 5/0628 {Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles [C12N 5/0666](#))}
- 5/0629 {Keratinocytes; Whole skin}
- 5/063 {Keratinocyte stem cells; Keratinocyte progenitors}
- 5/0631 {Mammary cells}
- 5/0632 {Cells of the oral mucosa}

- 5/0633 {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands}
- 5/0634 . . . {Cells from the blood or the immune system}

NOTE

Committed progenitors are classified with their progeny

WARNING

Group [C12N 5/0634](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0635 {B lymphocytes}

WARNING

Group [C12N 5/0635](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0636 {T lymphocytes}

WARNING

Group [C12N 5/0636](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0637 {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}

WARNING

Group [C12N 5/0637](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0638 {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}

WARNING

Group [C12N 5/0638](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

5/0639 {Dendritic cells, e.g. Langerhans cells in the epidermis}

WARNING

Group [C12N 5/0639](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

5/064 {Immunosuppressive dendritic cells}

WARNING

Group [C12N 5/064](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

5/0641 {Erythrocytes}

5/0642 {Granulocytes, e.g. basophils, eosinophils, neutrophils, mast cells}

5/0643 {Osteoclasts}

5/0644 {Platelets; Megakaryocytes}

5/0645 {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}

WARNING

Group [C12N 5/0645](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

5/0646 {Natural killers cells [NK], NKT cells}

WARNING

Group [C12N 5/0646](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#), [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

5/0647 {Haematopoietic stem cells; Uncommitted or multipotent progenitors}

5/0648 {Splenocytes}

5/065 {Thymocytes}

5/0651 {Lymph nodes}

5/0652 . . . {Cells of skeletal and connective tissues; Mesenchyme}

5/0653 {Adipocytes; Adipose tissue}

5/0654 {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}

5/0655 {Chondrocytes; Cartilage}

5/0656 {Adult fibroblasts}

5/0657 {Cardiomyocytes; Heart cells}

5/0658 {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}

5/0659 {Satellite cells}

5/066 {Tenocytes; Tendons, Ligaments}

5/0661 {Smooth muscle cells}

5/0662 {Stem cells}

5/0663 {Bone marrow mesenchymal stem cells (BM-MSC)}

5/0664 {Dental pulp stem cells, Dental follicle stem cells}

5/0665 {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}

5/0666 {Mesenchymal stem cells from hair follicles}

5/0667 {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}

5/0668 {Mesenchymal stem cells from other natural sources}

5/0669 {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow [C12N 5/0647](#), [C12N 5/0663](#))}

5/067 . . . {Hepatocytes}

5/0671 {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}

5/0672 {Stem cells; Progenitor cells; Precursor cells; Oval cells}

5/0676 . . . {Pancreatic cells}

5/0677 {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}

5/0678 {Stem cells; Progenitor cells; Precursor cells}

5/0679 . . . {Cells of the gastro-intestinal tract}

5/068 {Stem cells; Progenitors}

5/0681 . . . {Cells of the genital tract; Non-germinal cells from gonads}

5/0682 {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes [C12N 5/0609](#))}

5/0683 {Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia [C12N 5/061](#))}

5/0684 . . . {Cells of the urinary tract or kidneys}

5/0685 {Bladder epithelial cells}

5/0686 {Kidney cells}

5/0687 {Renal stem cells; Renal progenitors}

5/0688 . . . {Cells from the lungs or the respiratory tract}

5/0689 {Stem cells; Progenitors}

5/069 . . . {Vascular Endothelial cells}

5/0691 {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}

5/0692 {Stem cells; Progenitor cells; Precursor cells}

5/0693 . . . {Tumour cells; Cancer cells}

5/0694 {Cells of blood, e.g. leukemia cells, myeloma cells}

5/0695 {Stem cells; Progenitor cells; Precursor cells}

5/0696 . . . {Artificially induced pluripotent stem cells, e.g. iPS}

5/0697 . . {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels [C12N 5/0691](#))}

5/0698	. . . {Skin equivalents}	9/0026	. . . {acting on CH-NH groups of donors (1.5)}
5/10	. Cells modified by introduction of foreign genetic material	9/0028 {with NAD or NADP as acceptor (1.5.1)}
5/12	. . Fused cells, e.g. hybridomas	9/003 {Dihydrofolate reductase [DHFR] (1.5.1.3)}
5/14	. . . Plant cells	9/0032 {with oxygen as acceptor (1.5.3)}
5/16	. . . Animal cells	9/0034 {Sarcosine oxidase (1.5.3.1)}
5/163 {one of the fusion partners being a B or a T lymphocyte}	9/0036	. . . {acting on NADH or NADPH (1.6)}
5/166 {resulting from interspecies fusion}	9/0038 {with a heme protein as acceptor (1.6.2)}
7/00	Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K 39/00)	9/004 {Cytochrome-b5 reductase (1.6.2.2)}
	WARNING	9/0042 {NADPH-cytochrome P450 reductase (1.6.2.4)}
	From March 15, 2012 groups C12N 7/02 - C12N 7/08 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00 .	9/0044	. . . {acting on other nitrogen compounds as donors (1.7)}
7/02	. Recovery or purification	9/0046 {with oxygen as acceptor (1.7.3)}
7/025	. . {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}	9/0048 {Uricase (1.7.3.3)}
7/04	. Inactivation or attenuation; Producing viral sub-units	9/0051	. . {acting on a sulfur group of donors (1.8)}
7/045	. . {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}	9/0053	. . {acting on a heme group of donors (1.9)}
7/06	. . {Inactivation or attenuation} by chemical treatment	9/0055	. . {acting on diphenols and related substances as donors (1.10)}
7/08	. . {Inactivation or attenuation} by serial passage of virus	9/0057	. . . {with oxygen as acceptor (1.10.3)}
9/00	Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00; medicinal preparations containing enzymes or proenzymes A61K 38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00)	9/0059 {Catechol oxidase (1.10.3.1), i.e. tyrosinase}
	NOTE	9/0061 {Laccase (1.10.3.2)}
	Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.	9/0063 {Ascorbate oxidase (1.10.3.3)}
9/0002	. {Antibodies with enzymatic activity, e.g. abzymes}	9/0065	. . {acting on hydrogen peroxide as acceptor (1.11)}
9/0004	. {Oxidoreductases (1.)}	9/0067	. . {acting on hydrogen as donor (1.12)}
9/0006	. . {acting on CH-OH groups as donors (1.1)}	9/0069	. . {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
9/0008	. . {acting on the aldehyde or oxo group of donors (1.2)}	9/0071	. . {acting on paired donors with incorporation of molecular oxygen (1.14)}
9/001	. . {acting on the CH-CH group of donors (1.3)}	9/0073	. . . {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
9/0012	. . {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}	9/0075 {Nitric-oxide synthase (1.14.13.39)}
9/0014	. . . {acting on the CH-NH ₂ group of donors (1.4)}	9/0077	. . . {with a reduced iron-sulfur protein as one donor (1.14.15)}
9/0016 {with NAD or NADP as acceptor (1.4.1)}	9/0079 {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}
9/0018 {Phenylalanine dehydrogenase (1.4.1.20)}	9/0081 {Cholesterol monooxygenase (cytochrome P 450scs)(1.14.15.6)}
9/002 {with a cytochrome as acceptor (1.4.2)}	9/0083	. . . {Miscellaneous (1.14.99)}
9/0022 {with oxygen as acceptor (1.4.3)}	9/0085 {Steroid 17 alpha-monooxygenase (1.14.99.9)}
9/0024 {D-Amino acid oxidase (1.4.3.3)}	9/0087 {Steroid 21-monooxygenase (1.14.99.10)}
		9/0089	. . {acting on superoxide as acceptor (1.15)}
		9/0091	. . {oxidizing metal ions (1.16)}
		9/0093	. . {acting on CH or CH ₂ groups (1.17)}
		9/0095	. . {acting on iron-sulfur proteins as donor (1.18)}
		9/0097	. . {acting on reduced flavodoxin as donor (1.19)}
		9/10	. Transferases (2.) (ribonucleases C12N 9/22)
		9/1003	. . {transferring one-carbon groups (2.1)}
		9/1007	. . . {Methyltransferases (general) (2.1.1.)}
		9/1011 {Catechol O-methyltransferase (2.1.1.6)}
		9/1014 {Hydroxymethyl-, formyl-transferases (2.1.2)}
		9/1018 {Carboxy- and carbamoyl transferases (2.1.3)}
		9/1022	. . {transferring aldehyde or ketonic groups (2.2)}
		9/1025	. . {Acyltransferases (2.3)}
		9/1029	. . . {transferring groups other than amino-acyl groups (2.3.1)}
		9/1033 {Chloramphenicol O-acetyltransferase (2.3.1.28)}
		9/1037 {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}
		9/104	. . . {Aminoacyltransferases (2.3.2)}

9/1044 {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}	9/2411 {Amylases}
9/1048	. . {Glycosyltransferases (2.4)}	9/2414 {Alpha-amylase (3.2.1.1.)}
9/1051	. . . {Hexosyltransferases (2.4.1)}	9/2417 {from microbiological source}
9/1055 {Levansucrase (2.4.1.10)}	9/242 {Fungal source}
9/1059 {Cellulose synthases (2.4.1.12; 2.4.1.29)}	9/2422 {from plant source}
9/1062 {Sucrose synthase (2.4.1.13)}	9/2425 {Beta-amylase (3.2.1.2)}
9/1066 {Sucrose phosphate synthase (2.4.1.14)}	9/2428 {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}
9/107 {1,4-Alpha-glucan branching enzyme (2.4.1.18)}	9/2431 {Beta-fructofuranosidase (3.2.1.26), i.e. invertase}
9/1074 {Cyclomaltodextrin glucanotransferase (2.4.1.19)}	9/2434 {acting on beta-1,4-glucosidic bonds}
9/1077	. . . {Pentosyltransferases (2.4.2)}	9/2437 {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}
9/1081	. . . {transferring other glycosyl groups (2.4.99)}	9/244 {Endo-1,3(4)-beta-glucanase (3.2.1.6)}
9/1085	. . {transferring alkyl or aryl groups other than methyl groups (2.5)}	9/2442 {Chitinase (3.2.1.14)}
9/1088	. . . {Glutathione transferase (2.5.1.18)}	9/2445 {Beta-glucosidase (3.2.1.21)}
9/1092	. . . {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}	9/2448 {Licheninase (3.2.1.73)}
9/1096	. . {transferring nitrogenous groups (2.6)}	9/2451 {acting on alpha-1,6-glucosidic bonds}
9/12	. . transferring phosphorus containing groups, e.g. kinases (2.7)	9/2454 {Dextranase (3.2.1.11)}
9/1205	. . . {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}	9/2457 {Pullulanase (3.2.1.41)}
9/1211 {Thymidine kinase (2.7.1.21)}	9/246 {Isoamylase (3.2.1.68)}
9/1217	. . . {Phosphotransferases with a carboxyl group as acceptor (2.7.2)}	9/2462 {Lysozyme (3.2.1.17)}
9/1223	. . . {Phosphotransferases with a nitrogenous group as acceptor (2.7.3)}	9/2465 {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
9/1229	. . . {Phosphotransferases with a phosphate group as acceptor (2.7.4)}	9/2468 {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}
9/1235	. . . {Diphosphotransferases (2.7.6)}	9/2471 {Beta-galactosidase (3.2.1.23), i.e. exo-(1->4)-beta-D-galactanase}
9/1241	. . . {Nucleotidyltransferases (2.7.7)}	9/2474 {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}
9/1247 {DNA-directed RNA polymerase (2.7.7.6)}	9/2477 {Hemicellulases not provided in a preceding group}
9/1252 {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}	9/248 {Xylanases}
9/1258 {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}	9/2482 {Endo-1,4-beta-xylanase (3.2.1.8)}
9/1264 {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}	9/2485 {Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase}
9/127 {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}	9/2488 {Mannanases}
9/1276 {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}	9/2491 {Beta-mannosidase (3.2.1.25), i.e. mannanase}
9/1282 {RNA uridylyltransferase (2.7.7.52)}	9/2494 {Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase}
9/1288	. . . {Transferases for other substituted phosphate groups (2.7.8)}	9/2497	. . . {hydrolysing N- glycosyl compounds (3.2.2)}
9/1294	. . . {Phosphotransferases with paired acceptors (2.7.9)}	9/48	. . acting on peptide bonds (3.4)
9/13	. . {transferring sulfur containing groups (2.8)}	9/485	. . . {Exopeptidases (3.4.11-3.4.19)}
9/14	. Hydrolases (3)	9/50	. . . Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)}
9/16	. . acting on ester bonds (3.1)	9/503 {derived from viruses}
9/18	. . . Carboxylic ester hydrolases {(3.1.1)}	9/506 {derived from RNA viruses}
9/20 Triglyceride splitting, e.g. by means of lipase	9/52 derived from bacteria {or Archaea}
9/22	. . . Ribonucleases {RNAses, DNAses (catalytic nucleic acids C12N 15/113)}	NOTE	
9/24	. . acting on glycosyl compounds (3.2)	{In this group, Archaea, formerly known as Archaeobacteria, are classified with bacteria.}	
9/2402	. . . {hydrolysing O- and S- glycosyl compounds (3.2.1)}	9/54 bacteria being Bacillus
9/2405 {Glucanases}	9/58 derived from fungi
9/2408 {acting on alpha -1,4-glucosidic bonds}	9/60 from yeast
		9/62 from Aspergillus
		9/63 {derived from plants}
		9/64 derived from animal tissue
		9/6402 {from non-mammals}

9/6405	{ not being snakes }	9/86	. . .	acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}
9/6408	{ Serine endopeptidases (3.4.21) }	9/88	. Lyases (4.)	
9/641	{ Cysteine endopeptidases (3.4.22) }	9/90	. Isomerases (5.)	
9/6413	{ Aspartic endopeptidases (3.4.23) }	9/92	. . Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}	
9/6416	{ Metalloendopeptidases (3.4.24) }	9/93	. { Ligases (6) }	
9/6418	{ from snakes }	9/94	. Pancreatin	
9/6421	{ from mammals }	9/96	. Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates	
9/6424	{ Serine endopeptidases (3.4.21) }	9/98	. Preparation of granular or free-flowing enzyme compositions (C12N 9/96 takes precedence)	
9/6427	{ Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4) }	9/99	. Enzyme inactivation by chemical treatment	
9/6429	{ Thrombin (3.4.21.5) }	11/00	Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof	
9/6432	{ Coagulation factor Xa (3.4.21.6) }	11/02	. Enzymes or microbial cells immobilised on or in an organic carrier	
9/6435	{ Plasmin (3.4.21.7), i.e. fibrinolysin }	11/04	. . entrapped within the carrier, e.g. gel or hollow fibres	
9/6437	{ Coagulation factor VIIa (3.4.21.21) }	11/06	. . attached to the carrier via a bridging agent	
9/644	{ Coagulation factor IXa (3.4.21.22) }	11/08	. . the carrier being a synthetic polymer	
9/6443	{ Coagulation factor XIa (3.4.21.27) }	11/082	. . . obtained by reactions only involving carbon-to-carbon unsaturated bonds	
9/6445	{ Kallikreins (3.4.21.34; 3.4.21.35) }	11/084 Polymers containing vinyl alcohol units	
9/6448	{ Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37) }	11/087 Acrylic polymers	
9/6451	{ Coagulation factor XIIa (3.4.21.38) }	11/089	. . . obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds	
9/6454	{ Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases }	11/091 Phenol resins; Amino resins	
9/6456	{ Plasminogen activators }	11/093 Polyurethanes	
9/6459	{ t-plasminogen activator (3.4.21.68), i.e. tPA }	11/096 Polyesters; Polyamides	
9/6462	{ u-Plasminogen activator (3.4.21.73), i.e. urokinase }	11/098	. . . formed in the presence of the enzymes or microbial cells	
9/6464	{ Protein C (3.4.21.69) }	11/10	. . the carrier being a carbohydrate	
9/6467	{ Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79) }	11/12	. . . Cellulose or derivatives thereof	
9/647	{ Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups }	11/14	. Enzymes or microbial cells immobilised on or in an inorganic carrier	
9/6472	{ Cysteine endopeptidases (3.4.22) }	11/16	. Enzymes or microbial cells immobilised on or in a biological cell	
9/6475	{ Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63) }	11/18	. Multi-enzyme systems	
9/6478	{ Aspartic endopeptidases (3.4.23) }	13/00	Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves	
9/6481	{ Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3) }	15/00	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N 1/00, C12N 5/00, C12N 7/00; new plants per se A01H 4/00; plant reproduction by tissue culture techniques A01H 4/00; new animals per se A01K 67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00)	
9/6483	{ Chymosin (3.4.23.4), i.e. rennin }	15/01	. Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor	
9/6486	{ Renin (3.4.23.15) }	15/02	. Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies C07K 16/00; apparatus for cell fusion C12M) }	
9/6489	{ Metalloendopeptidases (3.4.24) }	15/03	. . Bacteria	
9/6491	{ Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23) }	15/04	. . Fungi	
9/6494	{ Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11 }	15/09	. Recombinant DNA-technology	
9/6497	{ Endothelin-converting enzyme (3.4.24.71) }			
9/78	. .	acting on carbon to nitrogen bonds other than peptide bonds (3.5)			
9/80	. . .	acting on amide bonds in linear amides {(3.5.1) }			
9/82	Asparaginase {(3.5.1.1) }			
9/84	Penicillin amidase {(3.5.1.11) }			

- 15/10 . . Processes for the isolation, preparation or purification of DNA or RNA ([chemical preparation of DNA or RNA C07H 21/00](#); [preparation of non-structural polynucleotides from microorganisms or with enzymes C12P 19/34](#))
- NOTE**
- {In groups [C12N 15/10](#) - [C12N 15/1096](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}.
- 15/1003 . . . {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- 15/1006 {by means of a solid support carrier, e.g. particles, polymers}
- 15/101 {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- 15/1013 {by using magnetic beads}
- 15/1017 {by filtration, e.g. using filters, frits, membranes}
- 15/102 . . . {Mutagenizing nucleic acids}
- 15/1024 {*In vivo* mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
- 15/1027 {by DNA shuffling, e.g. RSR, STEP, RPR}
- 15/1031 {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
- 15/1034 . . . {Isolating an individual clone by screening libraries}
- 15/1037 {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- 15/1041 {Ribosome/Polysome display, e.g. SPERT, ARM}
- 15/1044 {Preparation or screening of libraries displayed on scaffold proteins}
- 15/1048 {SELEX}
- 15/1051 {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- 15/1055 {Protein x Protein interaction, e.g. two hybrid selection}
- 15/1058 {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- 15/1062 {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- 15/1065 {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- 15/1068 {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}

- 15/1072 {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- 15/1075 {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- 15/1079 {Screening libraries by altering the phenotype or phenotypic trait of the host ([reporter assays C12N 15/1086](#))}
- 15/1082 {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- 15/1086 {Preparation or screening of expression libraries, e.g. reporter assays}
- 15/1089 {Design, preparation, screening or analysis of libraries using computer algorithms}
- 15/1093 {General methods of preparing gene libraries, not provided for in other subgroups}
- 15/1096 . . . {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- 15/11 . . DNA or RNA fragments; Modified forms thereof ([DNA or RNA not used in recombinant technology, C07H 21/00](#)); {Non-coding nucleic acids having a biological activity}

NOTE

Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups [C12N 15/11](#) - [C12N 15/117](#) cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The [C12N 2303/00](#) ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group [C12N 15/111](#)

- 15/111 . . . {General methods applicable to biologically active non-coding nucleic acids}
- 15/113 . . . Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing ([when used in plants C12N 15/8218](#))}
- 15/1131 {against viruses}
- 15/1132 {against retroviridae, e.g. HIV}
- 15/1133 {against herpesviridae, e.g. HSV}
- 15/1135 {against oncogenes or tumor suppressor genes}
- 15/1136 {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- 15/1137 {against enzymes ([viral enzymes C12N 15/1131](#); [receptors C12N 15/1138](#))}
- 15/1138 {against receptors or cell surface proteins}

- 15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}

NOTE

Aptamers fused to compounds which are already classified in groups [C12N 15/11](#) - [C12N 15/117](#), are classified with the corresponding compound

- 15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- 15/52 . . . Genes encoding for enzymes or proenzymes

NOTE

In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

- 15/62 . . . DNA sequences coding for fusion proteins

NOTE

In this group, the following term is used with the meaning indicated:

- "fusion" means the fusion of two different proteins.

- 15/625 . . . {containing a sequence coding for a signal sequence}
- 15/63 . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- 15/635 . . . {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline}
- 15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

NOTE

{In the group [C12N 15/64](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}

- 15/65 . . . using markers (enzymes used as markers [C12N 15/52](#))

NOTE

{In the group [C12N 15/65](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}

- 15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

NOTES

1. In this group, the following expression is used with the meaning indicated:
 - "non-functional linkers" means DNA sequences which are used to link DNA

sequences and which have no known function of structural gene or regulating function.

2. {In the group [C12N 15/66](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}

- 15/67 . . . General methods for enhancing the expression
- 15/68 Stabilisation of the vector
- 15/69 Increasing the copy number of the vector
- 15/70 . . . Vectors or expression systems specially adapted for E. coli

NOTES

1. This group covers the use of E. coli as host.
2. Shuttle vectors also replicating in E. coli are classified according to the other host.

- 15/71 Expression systems using regulatory sequences derived from the trp-operon
- 15/72 Expression systems using regulatory sequences derived from the lac-operon
- 15/73 Expression systems using phage (lambda) regulatory sequences
- 15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

NOTE

This group covers the use of prokaryotes as hosts.

- 15/743 {for Agrobacterium; Rhizobium; Bradyrhizobium}
- 15/746 {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}
- 15/75 for Bacillus
- 15/76 for Actinomyces; for Streptomyces
- 15/77 for Corynebacterium; for Brevibacterium
- 15/78 for Pseudomonas
- 15/79 . . . Vectors or expression systems specially adapted for eukaryotic hosts

NOTE

This group covers the use of eukaryotes as hosts.

- 15/80 for fungi
- 15/81 for yeasts
- 15/815 {for yeasts other than Saccharomyces}
- 15/82 for plant cells {, e.g. plant artificial chromosomes (PACs)}

WARNING

Documents are being continuously reclassified into this new classification scheme. See Warning notes below

- 15/8201 {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}

15/8202	{by biological means, e.g. cell mediated or natural vector}	15/8235	{Fruit-specific}
15/8203	{Virus mediated transformation}	15/8237	{Externally regulated expression systems}
15/8205	{Agrobacterium mediated transformation}	15/8238	{chemically inducible, e.g. tetracycline}
15/8206	{by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}	15/8239	{pathogen inducible}
15/8207	{by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}	15/8241	{Phenotypically and genetically modified plants via recombinant DNA technology}
15/8209	{Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}	15/8242	{with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}
		NOTE	15/8243	{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}
		Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in C12N 15/8209	15/8245	{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}
15/821	{Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}	15/8246	{Non-starch polysaccharides, e.g. cellulose, fructans, levans}
15/8212	{Colour markers, e.g. beta-glucuronidase [GUS], green fluorescent protein [GFP], carotenoid}	15/8247	{involving modified lipid metabolism, e.g. seed oil composition}
15/8213	{Targeted insertion of genes into the plant genome by homologous recombination}	15/8249	{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}
15/8214	{Plastid transformation}	15/825	{involving pigment biosynthesis}
15/8216	{Methods for controlling, regulating or enhancing expression of transgenes in plant cells}			NOTE
15/8217	{Gene switch}			Transgenic plants with altered flower morphology are also classified in this group
15/8218	{Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}	15/8251	{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}
15/822	{Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}	15/8253	{Methionine or cysteine}
15/8221	{Transit peptides}	15/8254	{Tryptophan or lysine}
15/8222	{Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}	15/8255	{involving lignin biosynthesis}
15/8223	{Vegetative tissue-specific promoters}	15/8257	{for the production of primary gene products, e.g. pharmaceutical products, interferon}
15/8225	{Leaf-specific, e.g. including petioles, stomata}	15/8258	{for the production of oral vaccines (antigens) or immunoglobulins}
15/8226	{Stem-specific, e.g. including tubers, beets}	15/8259	{Phytoremediation}
15/8227	{Root-specific}	15/8261	{with agronomic (input) traits, e.g. crop yield}
15/8229	{Meristem-specific, e.g. nodal, apical}	15/8262	{involving plant development}
15/823	{Reproductive tissue-specific promoters}	15/8263	{Ablation; Apoptosis}
15/8231	{Male-specific, e.g. anther, tapetum, pollen}	15/8265	{Transgene containment, e.g. gene dispersal}
15/8233	{Female-specific, e.g. pistil, ovule}	15/8266	{Abscission; Dehiscence; Senescence}
15/8234	{Seed-specific, e.g. embryo, endosperm}	15/8267	{Seed dormancy, germination or sprouting}
			15/8269	{Photosynthesis}
			15/827	{Flower development or morphology, e.g. flowering promoting factor [FPF]}
			15/8271	{for stress resistance, e.g. heavy metal resistance}
			15/8273	{for drought, cold, salt resistance}
			15/8274	{for herbicide resistance}
			15/8275	{Glyphosate}

15/8277	{Phosphinotricin}	15/8616	{Special methods for targeting systems}
15/8278	{Sulfonylurea}	15/863	Poxviral vectors, {e.g. entomopoxvirus}
15/8279	{for biotic stress resistance, pathogen resistance, disease resistance}	15/8633	{Avian poxviral vectors}
15/8281	{for bacterial resistance}	15/8636	{Vaccina virus vectors}
15/8282	{for fungal resistance}	15/864	Parvoviral vectors {, e.g. parvovirus, densovirus}
15/8283	{for virus resistance}	15/8645	{Adeno-associated virus}
15/8285	{for nematode resistance}	15/866	Baculoviral vectors
15/8286	{for insect resistance}	15/867	Retroviral vectors
15/8287	{for fertility modification, e.g. apomixis}	15/8673	{Special methods for packaging systems}
15/8289	{Male sterility}	15/8676	{Special methods for targeting systems}
15/829	{Female sterility}	15/869	Herpesviral vectors
15/8291	{Hormone-influenced development}	15/8695	{Herpes simplex virus-based vectors}
15/8293	{Abscisic acid [ABA]}	15/87	. .	Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
15/8294	{Auxins}	15/873	. . .	Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
15/8295	{Cytokinins}	15/877	Techniques for producing new mammalian cloned embryos
15/8297	{Gibberellins; GA3}	15/8771	{Bovine embryos}
15/8298	{Brassinosteroids}	15/8772	{Caprine embryos}
15/85	for animal cells	15/8773	{Ovine embryos}
15/8509	{for producing genetically modified animals, e.g. transgenic}	15/8775	{Murine embryos}
NOTE			15/8776	{Primate embryos}
Additional aspects of the modified animals are classified in the groups A01K 2207/00 - A01K 2267/00			15/8777	{Rabbit embryos}
2015/8518	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}	15/8778	{Swine embryos}
2015/8527	{for producing animal models, e.g. for tests or diseases}	15/88	. . .	using microencapsulation, e.g. using {amphiphile} liposome vesicle
2015/8536	{Animal models for genetic diseases}	15/89	. . .	using microinjection
2015/8545	{for Alzheimer"s disease}	15/895	{using biolistic methods}
2015/8554	{Invertebrates models for Alzheimer"s disease}	15/90	. . .	Stable introduction of foreign DNA into chromosome
2015/8563	{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}	15/902	{using homologous recombination}
2015/8572	{Animal models for proliferative diseases, e.g. comprising an oncogene}	15/905	{in yeast}
2015/8581	{Animal models for infectious diseases, e.g. AIDS}	15/907	{in mammalian cells}
2015/859	{Animal models comprising reporter system for screening tests}	2303/00 Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids		
15/86	Viral vectors	NOTE		
WARNING			Indexing codes of group C12N 2303/00 are only used in combination with group C12N 15/111		
From March 15, 2012 groups C12N 15/861 - C12N 15/869 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00 - C12N 2795/00			2310/00 Structure or type of the nucleic acid		
15/861	Adenoviral vectors	NOTE		
15/8613	{Chimaeric vector systems comprising heterologous sequences for production of another viral vector}	In groups C12N 2310/00 - C12N 2310/533 , C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N .		
			2310/10	. .	Type of nucleic acid
			2310/11	. .	Antisense
			2310/111	. . .	spanning the whole gene, or a large part of it
			2310/113	. . .	targeting other non-coding nucleic acids, e.g. antagomirs
			2310/12	. .	catalytic nucleic acids, e.g. ribozymes

2310/121	. . .	Hammerhead	2310/345	. . .	having at least two different backbone modifications
2310/122	. . .	Hairpin	2310/346	. . .	having a combination of backbone and sugar modifications
2310/123	. . .	Hepatitis delta	2310/35	. .	Nature of the modification
2310/124	. . .	based on group I or II introns	2310/351	. . .	Conjugate
2310/1241	Tetrahymena	2310/3511	intercalating or cleaving agent
2310/126	. . .	involving RNase P	2310/3513	Protein; Peptide
2310/127	. . .	DNAzymes	2310/3515	Lipophilic moiety, e.g. cholesterol
2310/128	. . .	processing or releasing ribozyme	2310/3517	Marker; Tag
2310/13	. .	Decoys	2310/3519	Fusion with another nucleic acid
2310/14	. .	interfering N.A.	2310/352	. . .	linked to the nucleic acid via a carbon atom
2310/141	. . .	MicroRNAs, miRNAs	2310/3521	Methyl
2310/15	. .	Nucleic acids forming more than 2 strands, e.g. TFOs	2310/3523	Allyl
2310/151	. . .	more than 3 strands, e.g. tetrads, H-DNA	2310/3525	MOE, methoxyethoxy
2310/152	. . .	on a single-stranded target, e.g. fold-back TFOs	2310/3527	Other alkyl chain
2310/153	. . .	with the aid of a protein, e.g. recombinase	2310/3529	Aromatic substituent
2310/16	. .	Aptamers	2310/353	. . .	linked to the nucleic acid via an atom other than carbon
2310/17	. .	Immunomodulatory nucleic acids	2310/3531	Hydrogen
2310/18	. .	acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17)	2310/3533	Halogen
2310/20	. .	involving clustered regularly interspaced short palindromic repeats [CRISPRs]	2310/3535	Nitrogen
2310/30	. .	Chemical structure	2310/50	. .	Physical structure
2310/31	. .	of the backbone	2310/51	. .	in polymeric form, e.g. multimers, concatemers
2310/311	. . .	Phosphotriesters	2310/52	. .	branched
2310/312	. . .	Phosphonates	2310/53	. .	partially self-complementary or closed
2310/3125	Methylphosphonates	2310/531	. . .	Stem-loop; Hairpin
2310/313	. . .	Phosphorodithioates	2310/532	. . .	Closed or circular
2310/314	. . .	Phosphoramidates	2310/533	. . .	having a mismatch or nick in at least one of the strands
2310/3145	with the nitrogen in 3' or 5'-position	2320/00	Applications; Uses	
2310/315	. . .	Phosphorothioates	2320/10	. .	in screening processes
2310/316	. . .	Phosphonothioates	2320/11	. .	for the determination of target sites, i.e. of active nucleic acids
2310/317	. . .	with an inverted bond, e.g. a cap structure	2320/12	. .	in functional genomics, i.e. for the determination of gene function
2310/318	. . .	where the PO2 is completely replaced, e.g. MMI or formacetal	2320/13	. .	in a process of directed evolution, e.g. SELEX, acquiring a new function
2310/3181	Peptide nucleic acid, PNA	2320/30	. .	Special therapeutic applications
2310/3183	Diol linkers, e.g. glycols or propanediols	2320/31	. .	Combination therapy
2310/319	. . .	linked by 2'-5' linkages, i.e. having a free 3'-position	2320/32	. .	Special delivery means, e.g. tissue-specific
2310/32	. .	of the sugar	2320/33	. .	Alteration of splicing
2310/321	. . .	2'-O-R Modification	2320/34	. .	Allele or polymorphism specific uses
2310/322	. . .	2'-R Modification	2320/35	. .	based on a specific dosage / administration regimen
2310/323	. . .	modified ring structure	2320/50	. .	Methods for regulating/modulating their activity
2310/3231	having an additional ring, e.g. LNA, ENA	2320/51	. .	modulating the chemical stability, e.g. nuclease-resistance
2310/3233	Morpholino-type ring	2320/52	. .	modulating the physical stability, e.g. GC-content
2310/3235	having the O of the ribose replaced by another atom	2320/53	. .	reducing unwanted side-effects
2310/33	. .	of the base	2330/00	Production	
2310/331	. . .	Universal or degenerate base	2330/10	. .	naturally occurring
2310/332	. . .	Abasic residue	2330/30	. .	chemically synthesised
2310/333	. . .	Modified A	2330/31	. .	Libraries, arrays
2310/334	. . .	Modified C	2330/50	. .	Biochemical production, i.e. in a transformed host cell
2310/3341	5-Methylcytosine	2330/51	. .	Specially adapted vectors
2310/335	. . .	Modified T or U	2500/00	Specific components of cell culture medium	
2310/336	. . .	Modified G	2500/02	. .	Atmosphere, e.g. low oxygen conditions
2310/337	. . .	in alpha-anomeric form	2500/05	. .	Inorganic components
2310/34	. .	Spatial arrangement of the modifications			
2310/341	. . .	Gapmers, i.e. of the type ===-----			
2310/342	. . .	Hemimers, i.e. of the type =====			
2310/343	. . .	having patterns, e.g. =====			
2310/344	. . .	Position-specific modifications, e.g. on every purine, at the 3'-end			

- 2500/10 . . Metals; Metal chelators ([cobalamine C12N 2500/38](#))
- 2500/12 . . . Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- 2500/14 Calcium; Ca chelators; Calcitonin
- 2500/16 Magnesium; Mg chelators
- 2500/20 Transition metals
- 2500/22 Zinc; Zn chelators ([insulin-zinc complexes C12N 2501/33](#))
- 2500/24 Iron; Fe chelators; Transferrin
- 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
- 2500/30 . Organic components ([metal chelators C12N 2500/10](#); [calcitonin C12N 2500/14](#); [transferrin C12N 2500/24](#))
- 2500/32 . . Amino acids
- 2500/33 . . . other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
- 2500/34 . . Sugars
- 2500/35 . . Polyols, e.g. glycerin, inositol
- 2500/36 . . Lipids
- 2500/38 . . Vitamins
- 2500/40 . . Nucleotides, nucleosides, bases ([cyclic nucleotides C12N 2501/01](#), [anti-neoplastic drugs C12N 2501/06](#))
- 2500/42 . . Organic phosphate, e.g. beta glycerophosphate
- 2500/44 . . Thiols, e.g. mercaptoethanol
- 2500/46 . . Amines, e.g. putrescine
- 2500/50 . Soluble polymers, e.g. polyethyleneglycol [PEG]
- 2500/60 . Buffer, e.g. pH regulation, osmotic pressure
- 2500/62 . . DMSO
- 2500/70 . Undefined extracts ([conditioned medium C12N 2502/00](#))
- 2500/72 . . from bacteria
- 2500/74 . . from fungi, e.g. yeasts
- 2500/76 . . from plants
- 2500/78 . . from protozoa
- 2500/80 . . from animals
- 2500/82 . . . from invertebrates
- 2500/84 . . . from mammals
- 2500/90 . Serum-free medium, which may still contain naturally-sourced components
- 2500/92 . . Medium free of human- or animal-derived components
- 2500/95 . . Protein-free medium and culture conditions
- 2500/98 . Xeno-free medium and culture conditions
- 2500/99 . Serum-free medium

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012.

The backlog of this group is being continuously reclassified to [C12N 2500/90](#) - [C12N 2500/98](#)

2501/00 Active agents used in cell culture processes, e.g. differentiation
NOTE

Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in [C07K 14/00](#), but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the

receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

- 2501/01 . Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- 2501/02 . Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- 2501/03 . Compounds acting on the NO pathway, e.g. nitrososarginine
- 2501/04 . Immunosuppressors, e.g. cyclosporin, tacrolimus
- 2501/05 . Adjuvants
- 2501/051 . . Lipid A (MPA, MPL)
- 2501/052 . . Lipopolysaccharides [LPS]
- 2501/054 . . Muramyle peptides
- 2501/056 . . Immunostimulating oligonucleotides, e.g. CpG
- 2501/06 . Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- 2501/065 . Modulators of histone acetylation
- 2501/07 . Heat shock proteins
- 2501/10 . Growth factors
- 2501/105 . . Insulin-like growth factors [IGF]
- 2501/11 . . Epidermal growth factor [EGF]
- 2501/113 . . Acidic fibroblast growth factor (aFGF, FGF-1)
- 2501/115 . . Basic fibroblast growth factor (bFGF, FGF-2)
- 2501/117 . . Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- 2501/119 . . Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- 2501/12 . . Hepatocyte growth factor [HGF]
- 2501/125 . . Stem cell factor [SCF], c-kit ligand [KL]
- 2501/13 . . Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- 2501/135 . . Platelet-derived growth factor [PDGF]
- 2501/14 . . Erythropoietin [EPO]
- 2501/145 . . Thrombopoietin [TPO]
- 2501/148 . . Transforming growth factor alpha [TGF- α]
- 2501/15 . . Transforming growth factor beta (TGF- β)
- 2501/155 . . Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- 2501/16 . . Activin; Inhibin; Mullerian inhibiting substance
- 2501/165 . . Vascular endothelial growth factor [VEGF]
- 2501/17 . . Angiopoietin
- 2501/175 . . Cardiotrophin
- 2501/18 . . Liver cell growth factor (LCGF, Gly-His-Lys)
- 2501/185 . . Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
- 2501/19 . . Growth and differentiation factors [GDF]
- 2501/195 . . Heregulin, neu differentiation factor
- 2501/20 . Cytokines; Chemokines
- 2501/21 . . Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- 2501/22 . . Colony stimulating factors (G-CSF, GM-CSF)
- 2501/23 . . Interleukins [IL]
- 2501/2301 . . . Interleukin-1 (IL-1)
- 2501/2302 . . . Interleukin-2 (IL-2)
- 2501/2303 . . . Interleukin-3 (IL-3)

2501/2304	. . . Interleukin-4 (IL-4)	2501/385	. . . of the family of the retinoic acid receptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
2501/2305	. . . Interleukin-5 (IL-5)	2501/39	. . . Steroid hormones
2501/2306	. . . Interleukin-6 (IL-6)	2501/392	. . . Sexual steroids
2501/2307	. . . Interleukin-7 (IL-7)	2501/395	. . . Thyroid hormones
2501/2308	. . . Interleukin-8 (IL-8)	2501/40	. Regulators of development
2501/2309	. . . Interleukin-9 (IL-9)	2501/405	. . Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
2501/231	. . . Interleukin-10 (IL-10)	2501/41	. . Hedgehog proteins; Cyclopamine (inhibitor)
2501/2311	. . . Interleukin-11 (IL-11)	2501/415	. . Wnt; Frizzled
2501/2312	. . . Interleukin-12 (IL-12)	2501/42	. . Notch; Delta; Jagged; Serrate
2501/2313	. . . Interleukin-13 (IL-13)	2501/48	. . Regulators of apoptosis
2501/2314	. . . Interleukin-14 (IL-14)	2501/50	. Cell markers; Cell surface determinants
2501/2315	. . . Interleukin-15 (IL-15)	2501/505	. . CD4; CD8
2501/2316	. . . Interleukin-16 (IL-16)	2501/51	. . B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
2501/2317	. . . Interleukin-17 (IL-17)	2501/515	. . CD3, T-cell receptor complex
2501/2318	. . . Interleukin-18 (IL-18)	2501/52	. . CD40, CD40-ligand (CD154)
2501/2319	. . . Interleukin-19 (IL-19)	2501/53	. . CD2
2501/232	. . . Interleukin-20 (IL-20)	2501/58	. . Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
2501/2321	. . . Interleukin-21 (IL-21)	2501/585	. . Integrins
2501/2322	. . . Interleukin-22 (IL-22)	2501/59	. . Lectins
2501/2323	. . . Interleukin-23 (IL-23)	2501/599	. . with CD designations not provided for elsewhere
2501/2324	. . . Interleukin-24 (IL-24)	2501/60	. Transcription factors
2501/2325	. . . Interleukin-25 (IL-25)	2501/602	. . Sox-2
2501/2326	. . . Interleukin-26 (IL-26)	2501/603	. . Oct-3/4
2501/2327	. . . Interleukin-27 (IL-27)	2501/604	. . Klf-4
2501/2328	. . . Interleukin-28 (IL-28)	2501/605	. . Nanog
2501/2329	. . . Interleukin-29 (IL-29)	2501/606	. . c-Myc
2501/233	. . . Interleukin-30 (IL-30)	2501/608	. . Lin28
2501/2331	. . . Interleukin-31 (IL-31)	2501/65	. MicroRNA
2501/2332	. . . Interleukin-32 (IL-32)	2501/70	. Enzymes
2501/2333	. . . Interleukin-33 (IL-33)	2501/71	. . Oxidoreductases (EC 1.)
2501/2334	. . . Interleukin-34 (IL-34)	2501/72	. . Transferases (EC 2.) (acetylation of histones C12N 2501/065)
2501/2335	. . . Interleukin-35 (IL-35)	2501/724	. . . Glycosyltransferases (EC 2.4.)
2501/235	. . . Leukemia inhibitory factor [LIF]	2501/727	. . . Kinases (EC 2.7.)
2501/237	. . Oncostatin M [OSM]	2501/73	. . Hydrolases (EC 3.)
2501/24	. . Interferons [IFN]	2501/734	. . . Proteases (EC 3.4.)
2501/25	. . Tumour necrosis factors [TNF]	2501/80	. Neurotransmitters; Neurohormones
2501/26	. . Flt-3 ligand (CD135L, flk-2 ligand)	2501/805	. . Acetylcholine
2501/30	. Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85)	2501/81	. . Adrenaline
2501/305	. . Growth hormone [GH], aka. somatotropin	2501/815	. . Dopamine
2501/31	. . Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins	2501/82	. . Histamine
2501/315	. . Prolactin	2501/825	. . Serotonine (5-HT); Melatonin
2501/32	. . Angiotensins [AT], angiotensinogen	2501/83	. . Tachykinins, e.g. substance P
2501/33	. . Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105)	2501/835	. . Neuropeptide Y [NPY]; Peptide YY [PYY]
2501/335	. . Glucagon; Glucagon-like peptide [GLP]; Exendin	2501/84	. . Excitatory amino acids
2501/34	. . Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin	2501/845	. . Gamma amino butyric acid [GABA]
2501/345	. . Gastrin; Cholecystokinins [CCK]	2501/85	. Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
2501/35	. . Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]	2501/855	. . Corticotropin [ACTH]
2501/355	. . Leptin	2501/86	. . Melanocyte-stimulating hormone [MSH]
2501/36	. . Somatostatin	2501/90	. Polysaccharides
2501/365	. . Endothelin	2501/905	. . Hyaluronic acid
2501/37	. . Parathyroid hormone [PTH]	2501/91	. . Heparin
2501/375	. . Thyroid stimulating hormone [TSH]	2501/998	. Proteins not provided for elsewhere
2501/38	. . with nuclear receptors		

NOTE

Classification by pathway does not apply.

2501/999 . Small molecules not provided for elsewhere

NOTE

Classification by pathway does not apply.

2502/00 Coculture with; Conditioned medium produced by

2502/02 . embryonic cells

2502/025 . . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

2502/03 . non-embryonic pluripotent stem cells

2502/04 . germ cells

2502/07 . endocrine cells

2502/072 . . adrenal cells

2502/074 . . pinealocytes

2502/076 . . pituitary cells

2502/078 . . thyroid, parathyroid cells

2502/08 . cells of the nervous system

2502/081 . . neurons

2502/083 . . sensory transducers

2502/085 . . eye cells

2502/086 . . glial cells

2502/088 . . neural stem cells

2502/09 . epidermal cells, skin cells, oral mucosa cells

2502/091 . . melanocytes

2502/092 . . hair cells

2502/094 . . keratinocytes

2502/095 . . mammary cells

2502/097 . . oral mucosa cells

2502/098 . . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands

2502/11 . blood or immune system cells

2502/1107 . . B cells

2502/1114 . . T cells

2502/1121 . . Dendritic cells

2502/1128 . . Erythrocytes

2502/1135 . . Granulocytes

2502/1142 . . Osteoclasts

2502/115 . . Platelets, megakaryocytes

2502/1157 . . Monocytes, macrophages

2502/1164 . . NK cells

2502/1171 . . Haematopoietic stem cells

2502/1178 . . Spleen cells

2502/1185 . . Thymus cells

2502/1192 . . Lymphatic cells

2502/13 . connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

2502/1305 . . Adipocytes

2502/1311 . . Osteocytes, osteoblasts, odontoblasts

2502/1317 . . Chondrocytes

2502/1323 . . Adult fibroblasts

2502/1329 . . Cardiomyocytes

2502/1335 . . Skeletal muscle cells, myocytes, myoblasts, myotubes

2502/1341 . . Tenocytes, cells from tendons and ligaments

2502/1347 . . Smooth muscle cells

2502/1352 . . Mesenchymal stem cells

2502/1358 . . . Bone marrow mesenchymal stem cells (BM- MSC)

2502/1364 . . . Dental pulp stem cells, dental follicle stem cells

2502/137 . . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood

2502/1376 . . . Mesenchymal stem cells from hair follicles

2502/1382 . . . Adipose-derived stem cells [ADSC], adipose stromal stem cells

2502/1388 . . . Mesenchymal stem cells from other natural sources

2502/1394 . . Bone marrow stromal cells; whole marrow

2502/14 . hepatocytes

2502/22 . pancreatic cells

2502/23 . Gastro-intestinal tract cells

2502/24 . Genital tract cells, non-germinal cells from gonads

2502/243 . . Cells of the female genital tract, non-germinal ovarian cells

2502/246 . . Cells of the male genital tract, non-germinal testis cells

2502/25 . Urinary tract cells, renal cells

2502/253 . . Bladder cells

2502/256 . . Renal cells

2502/27 . Lung cells, respiratory tract cells

2502/28 . Vascular endothelial cells

2502/30 . tumour cells

2502/45 . Artificially induced pluripotent stem cells

2502/50 . invertebrate cells

2502/70 . Non-animal cells

2502/99 . genetically modified cells

NOTE

Use [C12N 2501/00](#) to index the expressed products.

2503/00 Use of cells in diagnostics

2503/02 . Drug screening

2503/04 . Screening or testing on artificial tissues

2503/06 . . Screening or testing on artificial skin

2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells

NOTE

This scheme indexes the starting point of a differentiation process and is used in combination with classification in [C12N 5/06](#) for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

2506/02 . from embryonic cells

2506/025 . . from extra-embryonic cells, e.g. trophoblast, placenta

2506/03 . from non-embryonic pluripotent stem cells

2506/04 . from germ cells

2506/07 . from endocrine cells

2506/072 . . from adrenal cells

2506/074 . . from pinealocytes

2506/076 . . from pituitary cells

2506/078 . . from thyroid, parathyroid cells

2506/08 . from cells of the nervous system

2506/09 . from epidermal cells, from skin cells, from oral mucosa cells

2506/091 . . from melanocytes

2506/092 . . from hair cells

2506/094 . . from keratinocytes

2506/095 . . from mammary cells

2506/097 . . from oral mucosa cells

2506/098	. . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
2506/11	. from blood or immune system cells
2506/115	. . from monocytes, from macrophages
2506/13	. from connective tissue cells, from mesenchymal cells
2506/1307	. . from adult fibroblasts
2506/1315	. . from cardiomyocytes
2506/1323	. . from skeletal muscle cells
2506/133	. . from tenocytes
2506/1338	. . from smooth muscle cells
2506/1346	. . from mesenchymal stem cells
2506/1353	. . . from bone marrow mesenchymal stem cells (BM-MSC)
2506/1361	. . . from dental pulp or dental follicle stem cells
2506/1369	. . . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
2506/1376	. . . from mesenchymal stem cells derived from hair follicles
2506/1384	. . . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
2506/1392	. . . from mesenchymal stem cells from other natural sources
2506/14	. from hepatocytes
2506/22	. from pancreatic cells
2506/23	. from cells of the gastro-intestinal tract
2506/24	. from cells of the genital tract, from non-germinal gonad cells
2506/243	. . from cells of the female genital tract cells, from non-germinal ovarian cells
2506/246	. . from cells of the male genital tract cells, from non-germinal testis cells
2506/25	. from renal cells, from cells of the urinary tract
2506/27	. from lung cells, from cells of the respiratory tract
2506/28	. from vascular endothelial cells
2506/30	. from cancer cells, e.g. reversion of tumour cells

NOTE

Unless the tumorigenic phenotype is totally reversed, the end product is still classified under [C12N 5/0693](#).

2506/45	. from artificially induced pluripotent stem cells
2509/00	Methods for the dissociation of cells, e.g. specific use of enzymes
2509/10	. Mechanical dissociation
2510/00	Genetically modified cells
2510/02	. Cells for production
2510/04	. Immortalised cells
2511/00	Cells for large scale production
2513/00	3D culture
2517/00	Cells related to new breeds of animals
2517/02	. Cells from transgenic animals
2517/04	. Cells produced using nuclear transfer
2517/10	. Conditioning of cells for <u>in vitro</u> fecundation or nuclear transfer
2521/00	Culture process characterised by the use of hydrostatic pressure, flow or shear forces
2521/10	. Sound, e.g. ultrasounds

2523/00	Culture process characterised by temperature
2525/00	Culture process characterised by gravity, e.g. microgravity
2527/00	Culture process characterised by the use of mechanical forces, e.g. strain, vibration
2529/00	Culture process characterised by the use of electromagnetic stimulation
2529/10	. Stimulation by light
2531/00	Microcarriers
2533/00	Supports or coatings for cell culture, characterised by material
2533/10	. Mineral substrates
2533/12	. . Glass
2533/14	. . Ceramic
2533/18	. . Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
2533/20	. Small organic molecules
2533/30	. Synthetic polymers (thermoreactive polymers, e.g. PNIPAm, C12N 2539/10)
2533/32	. . Polylysine, polyornithine
2533/40	. . Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
2533/50	. Proteins
2533/52	. . Fibronectin; Laminin
2533/54	. . Collagen; Gelatin
2533/56	. . Fibrin; Thrombin
2533/70	. Polysaccharides
2533/72	. . Chitin, chitosan
2533/74	. . Alginate
2533/76	. . Agarose, agar-agar
2533/78	. . Cellulose
2533/80	. . Hyaluronan
2533/90	. Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
2533/92	. . Amnion; Decellularised dermis or mucosa
2535/00	Supports or coatings for cell culture characterised by topography
2535/10	. Patterned coating
2537/00	Supports and/or coatings for cell culture characterised by physical or chemical treatment
2537/10	. Cross-linking
2539/00	Supports and/or coatings for cell culture characterised by properties
2539/10	. Coating allowing for selective detachment of cells, e.g. thermoreactive coating

Viruses

2710/00	dsDNA viruses
2710/00011	. Details
2710/00021	. . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/00022	. . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/00023	. . Virus like particles [VLP]
2710/00031	. . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2710/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/00041 . . Use of virus, viral particle or viral elements as a vector
- 2710/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/00043 . . . viral genome or elements thereof as genetic vector
- 2710/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/00045 . . . Special targeting system for viral vectors
- 2710/00051 . . Methods of production or purification of viral material
- 2710/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/00061 . . Methods of inactivation or attenuation
- 2710/00062 . . . by genetic engineering
- 2710/00063 . . . by chemical treatment
- 2710/00064 . . . by serial passage
- 2710/00071 . . Demonstrated in vivo effect
- 2710/00088 . . for redistribution
- 2710/10011 . . Adenoviridae
- 2710/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10023 . . . Virus like particles [VLP]
- 2710/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10043 viral genome or elements thereof as genetic vector
- 2710/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10045 Special targeting system for viral vectors
- 2710/10051 . . . Methods of production or purification of viral material
- 2710/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10061 . . . Methods of inactivation or attenuation
- 2710/10062 by genetic engineering
- 2710/10063 by chemical treatment
- 2710/10064 by serial passage
- 2710/10071 . . . Demonstrated in vivo effect
- 2710/10088 . . . for redistribution
- 2710/10111 . . . Atadenovirus, e.g. ovine adenovirus D
- 2710/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10123 Virus like particles [VLP]
- 2710/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10141 Use of virus, viral particle or viral elements as a vector
- 2710/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10143 viral genome or elements thereof as genetic vector
- 2710/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10145 Special targeting system for viral vectors
- 2710/10151 Methods of production or purification of viral material
- 2710/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10161 Methods of inactivation or attenuation
- 2710/10162 by genetic engineering
- 2710/10163 by chemical treatment
- 2710/10164 by serial passage
- 2710/10171 Demonstrated in vivo effect
- 2710/10188 for redistribution
- 2710/10211 Aviadenovirus, e.g. fowl adenovirus A
- 2710/10221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10223 Virus like particles [VLP]
- 2710/10231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10241 Use of virus, viral particle or viral elements as a vector
- 2710/10242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10243 viral genome or elements thereof as genetic vector

- 2710/10244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10245 Special targeting system for viral vectors
- 2710/10251 Methods of production or purification of viral material
- 2710/10252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10261 Methods of inactivation or attenuation
- 2710/10262 by genetic engineering
- 2710/10263 by chemical treatment
- 2710/10264 by serial passage
- 2710/10271 Demonstrated in vivo effect
- 2710/10288 for redistribution
- 2710/10311 . . . Mastadenovirus, e.g. human or simian adenoviruses
- 2710/10321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10323 Virus like particles [VLP]
- 2710/10331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10341 Use of virus, viral particle or viral elements as a vector
- 2710/10342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10343 viral genome or elements thereof as genetic vector
- 2710/10344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10345 Special targeting system for viral vectors
- 2710/10351 Methods of production or purification of viral material
- 2710/10352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10361 Methods of inactivation or attenuation
- 2710/10362 by genetic engineering
- 2710/10363 by chemical treatment
- 2710/10364 by serial passage
- 2710/10371 Demonstrated in vivo effect
- 2710/10388 for redistribution
- 2710/12011 . . . Asfarviridae
- 2710/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/12023 . . . Virus like particles [VLP]
- 2710/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/12043 viral genome or elements thereof as genetic vector
- 2710/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/12045 Special targeting system for viral vectors
- 2710/12051 . . . Methods of production or purification of viral material
- 2710/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/12061 . . . Methods of inactivation or attenuation
- 2710/12062 by genetic engineering
- 2710/12063 by chemical treatment
- 2710/12064 by serial passage
- 2710/12071 . . . Demonstrated in vivo effect
- 2710/12088 . . . for redistribution
- 2710/14011 . . . Baculoviridae
- 2710/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/14023 . . . Virus like particles [VLP]
- 2710/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/14043 viral genome or elements thereof as genetic vectore
- 2710/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/14045 Special targeting system for viral vectors
- 2710/14051 . . . Methods of production or purification of viral material
- 2710/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/14061 . . . Methods of inactivation or attenuation
- 2710/14062 by genetic engineering
- 2710/14063 by chemical treatment

- 2710/14064 by serial passage
- 2710/14071 Demonstrated in vivo effect
- 2710/14088 for redistribution
- 2710/14111 Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- 2710/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/14123 Virus like particles [VLP]
- 2710/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/14141 Use of virus, viral particle or viral elements as a vector
- 2710/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/14143 viral genome or elements thereof as genetic vector
- 2710/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/14145 Special targeting system for viral vectors
- 2710/14151 Methods of production or purification of viral material
- 2710/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/14161 Methods of inactivation or attenuation
- 2710/14162 by genetic engineering
- 2710/14163 by chemical treatment
- 2710/14164 by serial passage
- 2710/14171 Demonstrated in vivo effect
- 2710/14188 For redistribution
- 2710/16011 Herpesviridae
- 2710/16021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16023 Virus like particles [VLP]
- 2710/16031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16041 Use of virus, viral particle or viral elements as a vector
- 2710/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16043 viral genome or elements thereof as genetic vector
- 2710/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16045 Special targeting system for viral vectors
- 2710/16051 Methods of production or purification of viral material
- 2710/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16061 Methods of inactivation or attenuation
- 2710/16062 by genetic engineering
- 2710/16063 by chemical treatment
- 2710/16064 by serial passage
- 2710/16071 Demonstrated in vivo effect
- 2710/16088 for redistribution
- 2710/16111 Cytomegalovirus, e.g. human herpesvirus 5
- 2710/16121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16123 Virus like particles [VLP]
- 2710/16131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16141 Use of virus, viral particle or viral elements as a vector
- 2710/16142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16143 viral genome or elements thereof as genetic vector
- 2710/16144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16145 Special targeting system for viral vectors
- 2710/16151 Methods of production or purification of viral material
- 2710/16152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16161 Methods of inactivation or attenuation
- 2710/16162 by genetic engineering
- 2710/16163 by chemical treatment
- 2710/16164 by serial passage
- 2710/16171 Demonstrated in vivo effect
- 2710/16188 for redistribution
- 2710/16211 Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- 2710/16221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16223 Virus like particles [VLP]

2710/16231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16361	Methods of inactivation or attenuation
2710/16232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16362	by genetic engineering
2710/16233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16363	by chemical treatment
2710/16234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16364	by serial passage
2710/16241	Use of virus, viral particle or viral elements as a vector	2710/16371	Demonstrated <u>in vivo</u> effect
2710/16242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16388	for redistribution
2710/16243	viral genome or elements thereof as genetic vector	2710/16411	. . .	Rhadinovirus, e.g. human herpesvirus 8
2710/16244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16421	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16245	Special targeting system for viral vectors	2710/16422	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16251	Methods of production or purification of viral material	2710/16423	Virus like particles [VLP]
2710/16252	relating to complementing cells and packaging systems for producing virus or viral particles	2710/16431	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16261	Methods of inactivation or attenuation	2710/16432	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16262	by genetic engineering	2710/16433	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16263	by chemical treatment	2710/16434	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16264	by serial passage	2710/16441	Use of virus, viral particle or viral elements as a vector
2710/16271	Demonstrated <u>in vivo</u> effect	2710/16442	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16288	for redistribution	2710/16443	viral genome or elements thereof as genetic vector
2710/16311	. . .	Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV	2710/16444	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16321	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/16445	Special targeting system for viral vectors
2710/16322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/16451	Methods of production or purification of viral material
2710/16323	Virus like particles [VLP]	2710/16452	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16461	Methods of inactivation or attenuation
2710/16332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16462	by genetic engineering
2710/16333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16463	by chemical treatment
2710/16334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16464	by serial passage
2710/16341	Use of virus, viral particle or viral elements as a vector	2710/16471	Demonstrated <u>in vivo</u> effect
2710/16342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16488	for redistribution
2710/16343	viral genome or elements thereof as genetic vector	2710/16511	. . .	Roseolovirus, e.g. human herpesvirus 6, 7
2710/16344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16521	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16345	Special targeting system for viral vectors	2710/16522	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16351	Methods of production or purification of viral material	2710/16523	Virus like particles [VLP]
2710/16352	relating to complementin g cells and packaging systems for producing virus or viral particles	2710/16531	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
			2710/16532	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
			2710/16533	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
			2710/16534	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
			2710/16541	Use of virus, viral particle or viral elements as a vector

- 2710/16542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16543 viral genome or elements thereof as genetic vector
- 2710/16544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16545 Special targeting system for viral vectors
- 2710/16551 Methods of production or purification of viral material
- 2710/16552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16561 Methods of inactivation or attenuation
- 2710/16562 by genetic engineering
- 2710/16563 by chemical treatment
- 2710/16564 by serial passage
- 2710/16571 Demonstrated in vivo effect
- 2710/16588 for redistribution
- 2710/16611 Simplexvirus, e.g. human herpesvirus 1, 2
- 2710/16621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16623 Virus like particles [VLP]
- 2710/16631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16641 Use of virus, viral particle or viral elements as a vector
- 2710/16642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16643 viral genome or elements thereof as genetic vector
- 2710/16644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16645 Special targeting system for viral vectors
- 2710/16651 Methods of production or purification of viral material
- 2710/16652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16661 Methods of inactivation or attenuation
- 2710/16662 by genetic engineering
- 2710/16663 by chemical treatment
- 2710/16664 by serial passage
- 2710/16671 Demonstrated in vivo effect
- 2710/16688 for redistribution
- 2710/16711 Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- 2710/16721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16723 Virus like particles [VLP]
- 2710/16731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16741 Use of virus, viral particle or viral elements as a vector
- 2710/16742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16743 viral genome or elements thereof as genetic vector
- 2710/16744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16745 Special targeting system for viral vectors
- 2710/16751 Methods of production or purification of viral material
- 2710/16752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16761 Methods of inactivation or attenuation
- 2710/16762 by genetic engineering
- 2710/16763 by chemical treatment
- 2710/16764 by serial passage
- 2710/16771 Demonstrated in vivo effect
- 2710/16788 for redistribution
- 2710/18011 Nimaviridae
- 2710/18021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/18022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/18023 Virus like particles [VLP]
- 2710/18031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/18032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/18033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/18034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/18041 Use of virus, viral particle or viral elements as a vector
- 2710/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/18043 viral genome or elements thereof as genetic vector
- 2710/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/18045 Special targeting system for viral vectors
- 2710/18051 Methods of production or purification of viral material
- 2710/18052 relating to complementing cells and packaging systems for producing virus or viral particles

- 2710/18061 . . . Methods of inactivation or attenuation
 2710/18062 by genetic engineering
 2710/18063 by chemical treatment
 2710/18064 by serial passage
 2710/18071 . . . Demonstrated in vivo effect
 2710/18088 . . . for redistribution
 2710/20011 . . Papillomaviridae
 2710/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
 2710/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
 2710/20023 . . . Virus like particles [VLP]
 2710/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
 2710/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
 2710/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
 2710/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
 2710/20041 . . . Use of virus, viral particle or viral elements as a vector
 2710/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
 2710/20043 viral genome or elements thereof as genetic vector
 2710/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
 2710/20045 Special targeting system for viral vectors
 2710/20051 . . . Methods of production or purification of viral material
 2710/20052 relating to complementing cells and packaging systems for producing virus or viral particles
 2710/20061 . . . Methods of inactivation or attenuation
 2710/20062 by genetic engineering
 2710/20063 by chemical treatment
 2710/20064 by serial passage
 2710/20071 . . . Demonstrated in vivo effect
 2710/20088 . . . for redistribution
 2710/22011 . . Polyomaviridae, e.g. polyoma, SV40, JC
 2710/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
 2710/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
 2710/22023 . . . Virus like particles [VLP]
 2710/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
 2710/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
 2710/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
 2710/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
 2710/22041 . . . Use of virus, viral particle or viral elements as a vector
 2710/22042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
 2710/22043 viral genome or elements thereof as genetic vector
 2710/22044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
 2710/22045 Special targeting system for viral vectors
 2710/22051 . . . Methods of production or purification of viral material
 2710/22052 relating to complementing cells and packaging systems for producing virus or viral particles
 2710/22061 . . . Methods of inactivation or attenuation
 2710/22062 by genetic engineering
 2710/22063 by chemical treatment
 2710/22064 by serial passage
 2710/22071 . . . Demonstrated in vivo effect
 2710/22088 . . . for redistribution
 2710/24011 . . Poxviridae
 2710/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
 2710/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
 2710/24023 . . . Virus like particles [VLP]
 2710/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
 2710/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
 2710/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
 2710/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
 2710/24041 . . . Use of virus, viral particle or viral elements as a vector
 2710/24042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
 2710/24043 viral genome or elements thereof as genetic vector
 2710/24044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
 2710/24045 Special targeting system for viral vectors
 2710/24051 . . . Methods of production or purification of viral material
 2710/24052 relating to complementing cells and packaging systems for producing virus or viral particles
 2710/24061 . . . Methods of inactivation or attenuation
 2710/24062 by genetic engineering
 2710/24063 by chemical treatment
 2710/24064 by serial passage
 2710/24071 . . . Demonstrated in vivo effect
 2710/24088 . . . for redistribution
 2710/24111 . . . Orthopoxvirus, e.g. vaccinia virus, variola
 2710/24121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
 2710/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
 2710/24123 Virus like particles [VLP]

- 2710/24131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24141 Use of virus, viral particle or viral elements as a vector
- 2710/24142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24143 viral genome or elements thereof as genetic vector
- 2710/24144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24145 Special targeting system for viral vectors
- 2710/24151 Methods of production or purification of viral material
- 2710/24152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24161 Methods of inactivation or attenuation
- 2710/24162 by genetic engineering
- 2710/24163 by chemical treatment
- 2710/24164 by serial passage
- 2710/24171 Demonstrated in vivo effect
- 2710/24188 for redistribution
- 2710/24211 . . . Parapoxvirus, e.g. Orf virus
- 2710/24221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24223 Virus like particles [VLP]
- 2710/24231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24241 Use of virus, viral particle or viral elements as a vector
- 2710/24242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24243 viral genome or elements thereof as genetic vector
- 2710/24244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24245 Special targeting system for viral vectors
- 2710/24251 Methods of production or purification of viral material
- 2710/24252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24261 Methods of inactivation or attenuation
- 2710/24262 by genetic engineering
- 2710/24263 by chemical treatment
- 2710/24264 by serial passage
- 2710/24271 Demonstrated in vivo effect
- 2710/24288 for redistribution
- 2720/00** **dsRNA viruses**
- 2720/00011 . Details
- 2720/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/00023 . . Virus like particles [VLP]
- 2720/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/00041 . . Use of virus, viral particle or viral elements as a vector
- 2720/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/00043 . . . viral genome or elements thereof as genetic vector
- 2720/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/00045 . . . Special targeting system for viral vectors
- 2720/00051 . . Methods of production or purification of viral material
- 2720/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/00061 . . Methods of inactivation or attenuation
- 2720/00062 . . . by genetic engineering
- 2720/00063 . . . by chemical treatment
- 2720/00064 . . . by serial passage
- 2720/00071 . . Demonstrated in vivo effect
- 2720/00088 . . for redistribution
- 2720/10011 . . Birnaviridae
- 2720/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/10023 . . . Virus like particles [VLP]
- 2720/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/10041 . . . Use of virus, viral particle or viral elements as a vector

2720/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2720/12131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/10043	viral genome or elements thereof as genetic vector	2720/12132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/10044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2720/12133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/10045	Special targeting system for viral vectors	2720/12134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/10051	. . .	Methods of production or purification of viral material	2720/12141	Use of virus, viral particle or viral elements as a vector
2720/10052	relating to complementing cells and packaging systems for producing virus or viral particles	2720/12142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/10061	. . .	Methods of inactivation or attenuation	2720/12143	viral genome or elements thereof as genetic vector
2720/10062	by genetic engineering	2720/12144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/10063	by chemical treatment	2720/12145	Special targeting system for viral vectors
2720/10064	by serial passage	2720/12151	Methods of production or purification of viral material
2720/10071	. . .	Demonstrated <u>in vivo</u> effect	2720/12152	relating to complementing cells and packaging systems for producing virus or viral particles
2720/10088	. . .	for redistribution	2720/12161	Methods of inactivation or attenuation
2720/12011	. .	Reoviridae	2720/12162	by genetic engineering
2720/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2720/12163	by chemical treatment
2720/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2720/12164	by serial passage
2720/12023	. . .	Virus like particles [VLP]	2720/12171	Demonstrated <u>in vivo</u> effect
2720/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2720/12188	for redistribution
2720/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2720/12211	. . .	Orthoreovirus, e.g. mammalian orthoreovirus
2720/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2720/12221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2720/12222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12041	. . .	Use of virus, viral particle or viral elements as a vector	2720/12223	Virus like particles [VLP]
2720/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2720/12231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12043	viral genome or elements thereof as genetic vector	2720/12232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2720/12233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12045	Special targeting system for viral vectors	2720/12234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12051	. . .	Methods of production or purification of viral material	2720/12241	Use of virus, viral particle or viral elements as a vector
2720/12052	relating to complementing cells and packaging systems for producing virus or viral particles	2720/12242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12061	. . .	Methods of inactivation or attenuation	2720/12243	viral genome or elements thereof as genetic vector
2720/12062	by genetic engineering	2720/12244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12063	by chemical treatment	2720/12245	Special targeting system for viral vectors
2720/12064	by serial passage	2720/12251	Methods of production or purification of viral material
2720/12071	. . .	Demonstrated <u>in vivo</u> effect	2720/12252	relating to complementing cells and packaging systems for producing virus or viral particles
2720/12088	. . .	for redistribution	2720/12261	Methods of inactivation or attenuation
2720/12111	. . .	Orbivirus, e.g. bluetongue virus			
2720/12121	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2720/12122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2720/12123	Virus like particles [VLP]			

- 2720/12262 by genetic engineering
- 2720/12263 by chemical treatment
- 2720/12264 by serial passage
- 2720/12271 Demonstrated in vivo effect
- 2720/12288 for redistribution
- 2720/12311 . . . Rotavirus, e.g. rotavirus A
- 2720/12321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12323 Virus like particles [VLP]
- 2720/12331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12341 Use of virus, viral particle or viral elements as a vector
- 2720/12342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12343 viral genome or elements thereof as genetic vector
- 2720/12344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12345 Special targeting system for viral vectors
- 2720/12351 Methods of production or purification of viral material
- 2720/12352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12361 Methods of inactivation or attenuation
- 2720/12362 by genetic engineering
- 2720/12363 by chemical treatment
- 2720/12364 by serial passage
- 2720/12371 Demonstrated in vivo effect
- 2720/12388 for redistribution
- 2730/00** **Reverse transcribing DNA viruses**
- 2730/00011 . Details
- 2730/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/00023 . . Virus like particles [VLP]
- 2730/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/00041 . . Use of virus, viral particle or viral elements as a vector
- 2730/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/00043 . . . viral genome or elements thereof as genetic vector
- 2730/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/00045 . . . Special targeting system for viral vectors
- 2730/00051 . . . Methods of production or purification of viral material
- 2730/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/00061 . . . Methods of inactivation or attenuation
- 2730/00062 . . . by genetic engineering
- 2730/00063 . . . by chemical treatment
- 2730/00064 . . . by serial passage
- 2730/00071 . . . Demonstrated in vivo effect
- 2730/00088 . . . for redistribution
- 2730/10011 . . . Hepadnaviridae
- 2730/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10023 . . . Virus like particles [VLP]
- 2730/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2730/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10043 viral genome or elements thereof as genetic vector
- 2730/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10045 Special targeting system for viral vectors
- 2730/10051 . . . Methods of production or purification of viral material
- 2730/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10061 . . . Methods of inactivation or attenuation
- 2730/10062 . . . by genetic engineering
- 2730/10063 . . . by chemical treatment
- 2730/10064 . . . by serial passage
- 2730/10071 . . . Demonstrated in vivo effect
- 2730/10088 . . . for redistribution
- 2730/10111 . . . Orthohepadnavirus, e.g. hepatitis B virus
- 2730/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10123 Virus like particles [VLP]

- 2730/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10141 Use of virus, viral particle or viral elements as a vector
- 2730/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10143 viral genome or elements thereof as genetic vector
- 2730/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10145 Special targeting system for viral vectors
- 2730/10151 Methods of production or purification of viral material
- 2730/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10161 Methods of inactivation or attenuation
- 2730/10162 by genetic engineering
- 2730/10163 by chemical treatment
- 2730/10164 by serial passage
- 2730/10171 Demonstrated *in vivo* effect
- 2730/10188 for redistribution
- 2740/00** **Reverse transcribing RNA viruses**
- 2740/00011 . Details
- 2740/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/00023 . . Virus like particles [VLP]
- 2740/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/00041 . . Use of virus, viral particle or viral elements as a vector
- 2740/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/00043 . . . viral genome or elements thereof as genetic vector
- 2740/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/00045 . . . Special targeting system for viral vectors
- 2740/00051 . . Methods of production or purification of viral material
- 2740/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/00061 . . Methods of inactivation or attenuation
- 2740/00062 . . . by genetic engineering
- 2740/00063 . . . by chemical treatment
- 2740/00064 . . . by serial passage
- 2740/00071 . . Demonstrated *in vivo* effect
- 2740/00088 . . for redistribution
- 2740/10011 . . Retroviridae
- 2740/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/10023 . . . Virus like particles [VLP]
- 2740/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2740/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/10043 viral genome or elements thereof as genetic vector
- 2740/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/10045 Special targeting system for viral vectors
- 2740/10051 . . . Methods of production or purification of viral material
- 2740/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/10061 . . . Methods of inactivation or attenuation
- 2740/10062 by genetic engineering
- 2740/10063 by chemical treatment
- 2740/10064 by serial passage
- 2740/10071 . . . Demonstrated *in vivo* effect
- 2740/10088 . . . for redistribution
- 2740/11011 . . . Alpharetrovirus, e.g. avian leucosis virus
- 2740/11021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/11022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/11023 Virus like particles [VLP]
- 2740/11031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/11032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/11033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/11034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/11041 Use of virus, viral particle or viral elements as a vector

2740/11042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/13023	Virus like particles [VLP]
2740/11043	viral genome or elements thereof as genetic vector	2740/13031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/11044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/13032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/11045	Special targeting system for viral vectors	2740/13033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/11051	Methods of production or purification of viral material	2740/13034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/11052	relating to complementing cells and packaging systems for producing virus or viral particles	2740/13041	Use of virus, viral particle or viral elements as a vector
2740/11061	Methods of inactivation or attenuation	2740/13042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/11062	by genetic engineering	2740/13043	viral genome or elements thereof as genetic vector
2740/11063	by chemical treatment	2740/13044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/11064	by serial passage	2740/13045	Special targeting system for viral vectors
2740/11071	Demonstrated <u>in vivo</u> effect	2740/13051	Methods of production or purification of viral material
2740/11088	for redistribution	2740/13052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/12011	. . .	Betaretrovirus, e.g. mouse mammary tumour virus	2740/13061	Methods of inactivation or attenuation
2740/12021	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/13062	by genetic engineering
2740/12022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/13063	by chemical treatment
2740/12023	Virus like particles [VLP]	2740/13064	by serial passage
2740/12031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/13071	Demonstrated <u>in vivo</u> effect
2740/12032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/13088	for redistribution
2740/12033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/14011	. . .	Deltaretrovirus, e.g. bovine leukaemia virus
2740/12034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/14021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/12041	Use of virus, viral particle or viral elements as a vector	2740/14022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/14023	Virus like particles [VLP]
2740/12043	viral genome or elements thereof as genetic vector	2740/14031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/14032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/12045	Special targeting system for viral vectors	2740/14033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/12051	Methods of production or purification of viral material	2740/14034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/12052	relating to complementing cells and packaging systems for producing virus or viral particles	2740/14041	Use of virus, viral particle or viral elements as a vector
2740/12061	Methods of inactivation or attenuation	2740/14042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/12062	by genetic engineering	2740/14043	viral genome or elements thereof as genetic vector
2740/12063	by chemical treatment	2740/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/12064	by serial passage	2740/14045	Special targeting system for viral vectors
2740/12071	Demonstrated <u>in vivo</u> effect	2740/14051	Methods of production or purification of viral material
2740/12088	for redistribution	2740/14052	relating to complementing cells and packaging systems for producing virus or viral particles
2740/13011	. . .	Gammaretrovirus, e.g. murine leukaemia virus			
2740/13021	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2740/13022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			

- 2740/14061 Methods of inactivation or attenuation
- 2740/14062 by genetic engineering
- 2740/14063 by chemical treatment
- 2740/14064 by serial passage
- 2740/14071 Demonstrated in vivo effect
- 2740/14088 for redistribution
- 2740/15011 Lentivirus, not HIV, e.g. FIV, SIV
- 2740/15021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/15022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/15023 Virus like particles [VLP]
- 2740/15031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/15032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/15033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/15034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/15041 Use of virus, viral particle or viral elements as a vector
- 2740/15042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/15043 viral genome or elements thereof as genetic vector
- 2740/15044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/15045 Special targeting system for viral vectors
- 2740/15051 Methods of production or purification of viral material
- 2740/15052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/15061 Methods of inactivation or attenuation
- 2740/15062 by genetic engineering
- 2740/15063 by chemical treatment
- 2740/15064 by serial passage
- 2740/15071 Demonstrated in vivo effect
- 2740/15088 for redistribution
- 2740/16011 Human Immunodeficiency Virus, HIV
- 2740/16021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/16022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16023 Virus like particles [VLP]
- 2740/16031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/16032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/16033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16041 Use of virus, viral particle or viral elements as a vector
- 2740/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/16043 viral genome or elements thereof as genetic vector
- 2740/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/16045 Special targeting system for viral vectors
- 2740/16051 Methods of production or purification of viral material
- 2740/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/16061 Methods of inactivation or attenuation
- 2740/16062 by genetic engineering
- 2740/16063 by chemical treatment
- 2740/16064 by serial passage
- 2740/16071 Demonstrated in vivo effect
- 2740/16088 for redistribution
- 2740/16111 concerning HIV env
- 2740/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16171 Demonstrated in vivo effect
- 2740/16188 for redistribution
- 2740/16211 concerning HIV gagpol
- 2740/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16271 Demonstrated in vivo effect
- 2740/16288 for redistribution
- 2740/16311 concerning HIV regulatory proteins
- 2740/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16371 Demonstrated in vivo effect
- 2740/16388 for redistribution
- 2740/17011 Spumavirus, e.g. chimpanzee foamy virus
- 2740/17021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/17022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/17023 Virus like particles [VLP]
- 2740/17031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/17032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/17033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/17034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

- 2740/17041 Use of virus, viral particle or viral elements as a vector
- 2740/17042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/17043 viral genome or elements thereof as genetic vector
- 2740/17044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/17045 Special targeting system for viral vectors
- 2740/17051 Methods of production or purification of viral material
- 2740/17052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/17061 Methods of inactivation or attenuation
- 2740/17062 by genetic engineering
- 2740/17063 by chemical treatment
- 2740/17064 by serial passage
- 2740/17071 Demonstrated in vivo effect
- 2740/17088 for redistribution
- 2750/00 ssDNA viruses**
- 2750/00011 . Details
- 2750/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/00023 . . Virus like particles [VLP]
- 2750/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/00041 . . Use of virus, viral particle or viral elements as a vector
- 2750/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/00043 . . . viral genome or elements thereof as genetic vector
- 2750/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/00045 . . . Special targeting system for viral vectors
- 2750/00051 . . Methods of production or purification of viral material
- 2750/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/00061 . . Methods of inactivation or attenuation
- 2750/00062 . . . by genetic engineering
- 2750/00063 . . . by chemical treatment
- 2750/00064 . . . by serial passage
- 2750/00071 . . Demonstrated in vivo effect
- 2750/00088 . . for redistribution
- 2750/10011 . . Circoviridae
- 2750/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/10023 . . . Virus like particles [VLP]
- 2750/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/10043 viral genome or elements thereof as genetic vector
- 2750/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/10045 Special targeting system for viral vectors
- 2750/10051 . . . Methods of production or purification of viral material
- 2750/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/10061 . . . Methods of inactivation or attenuation
- 2750/10062 by genetic engineering
- 2750/10063 by chemical treatment
- 2750/10064 by serial passage
- 2750/10071 . . . Demonstrated in vivo effect
- 2750/10088 . . . for redistribution
- 2750/12011 . . Geminiviridae
- 2750/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/12023 . . . Virus like particles [VLP]
- 2750/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/12043 viral genome or elements thereof as genetic vector
- 2750/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/12045 Special targeting system for viral vectors
- 2750/12051 . . . Methods of production or purification of viral material

- 2750/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/12061 . . . Methods of inactivation or attenuation
- 2750/12062 . . . by genetic engineering
- 2750/12063 . . . by chemical treatment
- 2750/12064 . . . by serial passage
- 2750/12071 . . . Demonstrated in vivo effect
- 2750/12088 . . . for redistribution
- 2750/14011 . . . Parvoviridae
- 2750/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14023 . . . Virus like particles [VLP]
- 2750/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14043 . . . viral genome or elements thereof as genetic vector
- 2750/14044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14045 . . . Special targeting system for viral vectors
- 2750/14051 . . . Methods of production or purification of viral material
- 2750/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14061 . . . Methods of inactivation or attenuation
- 2750/14062 . . . by genetic engineering
- 2750/14063 . . . by chemical treatment
- 2750/14064 . . . by serial passage
- 2750/14071 . . . Demonstrated in vivo effect
- 2750/14088 . . . for redistribution
- 2750/14111 . . . Dependovirus, e.g. adenoassociated viruses
- 2750/14121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14123 . . . Virus like particles [VLP]
- 2750/14131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14141 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14143 . . . viral genome or elements thereof as genetic vector
- 2750/14144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14145 . . . Special targeting system for viral vectors
- 2750/14151 . . . Methods of production or purification of viral material
- 2750/14152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14161 . . . Methods of inactivation or attenuation
- 2750/14162 . . . by genetic engineering
- 2750/14163 . . . by chemical treatment
- 2750/14164 . . . by serial passage
- 2750/14171 . . . Demonstrated in vivo effect
- 2750/14188 . . . for redistribution
- 2750/14211 . . . Erythrovirus, e.g. B19 virus
- 2750/14221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14223 . . . Virus like particles [VLP]
- 2750/14231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14241 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14242 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14243 . . . viral genome or elements thereof as genetic vector
- 2750/14244 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14245 . . . Special targeting system for viral vectors
- 2750/14251 . . . Methods of production or purification of viral material
- 2750/14252 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14261 . . . Methods of inactivation or attenuation
- 2750/14262 . . . by genetic engineering
- 2750/14263 . . . by chemical treatment
- 2750/14264 . . . by serial passage
- 2750/14271 . . . Demonstrated in vivo effect
- 2750/14288 . . . for redistribution
- 2750/14311 . . . Parvovirus, e.g. minute virus of mice
- 2750/14321 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

- 2750/14322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14323 Virus like particles [VLP]
- 2750/14331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14341 Use of virus, viral particle or viral elements as a vector
- 2750/14342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14343 viral genome or elements thereof as genetic vector
- 2750/14344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14345 Special targeting system for viral vectors
- 2750/14351 Methods of production or purification of viral material
- 2750/14352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14361 Methods of inactivation or attenuation
- 2750/14362 by genetic engineering
- 2750/14363 by chemical treatment
- 2750/14364 by serial passage
- 2750/14371 Demonstrated *in vivo* effect
- 2750/14388 for redistribution
- 2760/00** **ssRNA viruses negative-sense**
- 2760/00011 . Details
- 2760/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/00023 . . Virus like particles [VLP]
- 2760/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/00041 . . Use of virus, viral particle or viral elements as a vector
- 2760/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/00043 . . . viral genome or elements thereof as genetic vector
- 2760/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/00045 . . . Special targeting system for viral vectors
- 2760/00051 . . Methods of production or purification of viral material
- 2760/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/00061 . . Methods of inactivation or attenuation
- 2760/00062 . . . by genetic engineering
- 2760/00063 . . . by chemical treatment
- 2760/00064 . . . by serial passage
- 2760/00071 . . Demonstrated *in vivo* effect
- 2760/00088 . . for redistribution
- 2760/10011 . . Arenaviridae
- 2760/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10023 . . . Virus like particles [VLP]
- 2760/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10043 viral genome or elements thereof as genetic vector
- 2760/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10045 Special targeting system for viral vectors
- 2760/10051 . . . Methods of production or purification of viral material
- 2760/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10061 . . . Methods of inactivation or attenuation
- 2760/10062 by genetic engineering
- 2760/10063 by chemical treatment
- 2760/10064 by serial passage
- 2760/10071 . . . Demonstrated *in vivo* effect
- 2760/10088 . . . for redistribution
- 2760/10111 . . . Deltavirus, e.g. hepatitis delta virus
- 2760/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10123 Virus like particles [VLP]
- 2760/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2760/10134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/12121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/10141	Use of virus, viral particle or viral elements as a vector	2760/12122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/10142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/12123	Virus like particles [VLP]
2760/10143	viral genome or elements thereof as genetic vector	2760/12131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/10144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/12132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/10145	Special targeting system for viral vectors	2760/12133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/10151	Methods of production or purification of viral material	2760/12134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/10152	relating to complementing cells and packaging systems for producing virus or viral particles	2760/12141	Use of virus, viral particle or viral elements as a vector
2760/10161	Methods of inactivation or attenuation	2760/12142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/10162	by genetic engineering	2760/12143	viral genome or elements thereof as genetic vector
2760/10163	by chemical treatment	2760/12144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/10164	by serial passage	2760/12145	Special targeting system for viral vectors
2760/10171	Demonstrated <u>in vivo</u> effect	2760/12151	Methods of production or purification of viral material
2760/10188	for redistribution	2760/12152	relating to complementing cells and packaging systems for producing virus or viral particles
2760/12011	. .	Bunyaviridae	2760/12161	Methods of inactivation or attenuation
2760/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/12162	by genetic engineering
2760/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/12163	by chemical treatment
2760/12023	. . .	Virus like particles [VLP]	2760/12164	by serial passage
2760/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/12171	Demonstrated <u>in vivo</u> effect
2760/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/12188	for redistribution
2760/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/12211	. . .	Phlebovirus, e.g. Rift Valley fever virus
2760/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/12221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/12041	. . .	Use of virus, viral particle or viral elements as a vector	2760/12222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/12223	Virus like particles [VLP]
2760/12043	viral genome or elements thereof as genetic vector	2760/12231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/12232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/12045	Special targeting system for viral vectors	2760/12233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/12051	. . .	Methods of production or purification of viral material	2760/12234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/12052	relating to complementing cells and packaging systems for producing virus or viral particles	2760/12241	Use of virus, viral particle or viral elements as a vector
2760/12061	. . .	Methods of inactivation or attenuation	2760/12242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/12062	by genetic engineering	2760/12243	viral genome or elements thereof as genetic vector
2760/12063	by chemical treatment	2760/12244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/12064	by serial passage	2760/12245	Special targeting system for viral vectors
2760/12071	. . .	Demonstrated <u>in vivo</u> effect			
2760/12088	. . .	for redistribution			
2760/12111	. . .	Hantavirus, e.g. Hantaan virus			

- 2760/12251 Methods of production or purification of viral material
- 2760/12252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12261 Methods of inactivation or attenuation
- 2760/12262 by genetic engineering
- 2760/12263 by chemical treatment
- 2760/12264 by serial passage
- 2760/12271 Demonstrated in vivo effect
- 2760/12288 for redistribution
- 2760/14011 . . Filoviridae
- 2760/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14023 . . . Virus like particles [VLP]
- 2760/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14043 viral genome or elements thereof as genetic vector
- 2760/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14045 Special targeting system for viral vectors
- 2760/14051 . . . Methods of production or purification of viral material
- 2760/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14061 . . . Methods of inactivation or attenuation
- 2760/14062 by genetic engineering
- 2760/14063 by chemical treatment
- 2760/14064 by serial passage
- 2760/14071 . . . Demonstrated in vivo effect
- 2760/14088 . . . for redistribution
- 2760/14111 . . . Ebolavirus, e.g. Zaire ebolavirus
- 2760/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14123 Virus like particles [VLP]
- 2760/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14141 Use of virus, viral particle or viral elements as a vector
- 2760/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14143 viral genome or elements thereof as genetic vector
- 2760/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14145 Special targeting system for viral vectors
- 2760/14151 Methods of production or purification of viral material
- 2760/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14161 Methods of inactivation or attenuation
- 2760/14162 by genetic engineering
- 2760/14163 by chemical treatment
- 2760/14164 by serial passage
- 2760/14171 Demonstrated in vivo effect
- 2760/14188 for redistribution
- 2760/14211 . . . Marburgvirus, e.g. lake Victoria marburgvirus
- 2760/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14223 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14241 Use of virus, viral particle or viral elements as a vector
- 2760/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14243 viral genome or elements thereof as genetic vector
- 2760/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14245 Special targeting system for viral vectors
- 2760/14251 Methods of production or purification of viral material
- 2760/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14261 Methods of inactivation or attenuation
- 2760/14262 by genetic engineering
- 2760/14263 by chemical treatment
- 2760/14264 by serial passage
- 2760/14271 Demonstrated in vivo effect
- 2760/14288 for redistribution
- 2760/16011 . . Orthomyxoviridae

- 2760/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16023 . . . Virus like particles [VLP]
- 2760/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/16042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16043 . . . viral genome or elements thereof as genetic vector
- 2760/16044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16045 . . . Special targeting system for viral vectors
- 2760/16051 . . . Methods of production or purification of viral material
- 2760/16052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16061 . . . Methods of inactivation or attenuation
- 2760/16062 . . . by genetic engineering
- 2760/16063 . . . by chemical treatment
- 2760/16064 . . . by serial passage
- 2760/16071 . . . Demonstrated in vivo effect
- 2760/16088 . . . for redistribution
- 2760/16111 . . . Influenzavirus A, i.e. influenza A virus
- 2760/16121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16123 . . . Virus like particles [VLP]
- 2760/16131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16141 . . . Use of virus, viral particle or viral elements as a vector
- 2760/16142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16143 . . . viral genome or elements thereof as genetic vector
- 2760/16144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16145 . . . Special targeting system for viral vectors
- 2760/16151 . . . Methods of production or purification of viral material
- 2760/16152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16161 . . . Methods of inactivation or attenuation
- 2760/16162 . . . by genetic engineering
- 2760/16163 . . . by chemical treatment
- 2760/16164 . . . by serial passage
- 2760/16171 . . . Demonstrated in vivo effect
- 2760/16188 . . . for redistribution
- 2760/16211 . . . Influenzavirus B, i.e. influenza B virus
- 2760/16221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16223 . . . Virus like particles [VLP]
- 2760/16231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16241 . . . Use of virus, viral particle or viral elements as a vector
- 2760/16242 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16243 . . . viral genome or elements thereof as genetic vector
- 2760/16244 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16245 . . . Special targeting system for viral vectors
- 2760/16251 . . . Methods of production or purification of viral material
- 2760/16252 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16261 . . . Methods of inactivation or attenuation
- 2760/16262 . . . by genetic engineering
- 2760/16263 . . . by chemical treatment
- 2760/16264 . . . by serial passage
- 2760/16271 . . . Demonstrated in vivo effect
- 2760/16288 . . . for redistribution
- 2760/16311 . . . Influenzavirus C, i.e. influenza C virus
- 2760/16321 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16322 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16323 . . . Virus like particles [VLP]
- 2760/16331 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16332 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16333 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- 2760/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16341 Use of virus, viral particle or viral elements as a vector
- 2760/16342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16343 viral genome or elements thereof as genetic vector
- 2760/16344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16345 Special targeting system for viral vectors
- 2760/16351 Methods of production or purification of viral material
- 2760/16352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16361 Methods of inactivation or attenuation
- 2760/16362 by genetic engineering
- 2760/16363 by chemical treatment
- 2760/16364 by serial passage
- 2760/16371 Demonstrated in vivo effect
- 2760/16388 for redistribution
- 2760/18011 . . Paramyxoviridae
- 2760/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18023 . . . Virus like particles [VLP]
- 2760/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18043 viral genome or elements thereof as genetic vector
- 2760/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18045 Special targeting system for viral vectors
- 2760/18051 . . . Methods of production or purification of viral material
- 2760/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18061 . . . Methods of inactivation or attenuation
- 2760/18062 by genetic engineering
- 2760/18063 by chemical treatment
- 2760/18064 by serial passage
- 2760/18071 . . . Demonstrated in vivo effect
- 2760/18088 . . . for redistribution
- 2760/18111 . . . Avulavirus, e.g. Newcastle disease virus
- 2760/18121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18123 Virus like particles [VLP]
- 2760/18131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18141 Use of virus, viral particle or viral elements as a vector
- 2760/18142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18143 viral genome or elements thereof as genetic vector
- 2760/18144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18145 Special targeting system for viral vectors
- 2760/18151 Methods of production or purification of viral material
- 2760/18152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18161 Methods of inactivation or attenuation
- 2760/18162 by genetic engineering
- 2760/18163 by chemical treatment
- 2760/18164 by serial passage
- 2760/18171 Demonstrated in vivo effect
- 2760/18188 for redistribution
- 2760/18211 . . . Henipavirus, e.g. hendra virus
- 2760/18221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18223 Virus like particles [VLP]
- 2760/18231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18241 Use of virus, viral particle or viral elements as a vector
- 2760/18242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18243 viral genome or elements thereof as genetic vector
- 2760/18244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18245 Special targeting system for viral vectors

- 2760/18251 Methods of production or purification of viral material
- 2760/18252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18261 Methods of inactivation or attenuation
- 2760/18262 by genetic engineering
- 2760/18263 by chemical treatment
- 2760/18264 by serial passage
- 2760/18271 Demonstrated in vivo effect
- 2760/18288 for redistribution
- 2760/18311 . . . Metapneumovirus, e.g. avian pneumovirus
- 2760/18321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18323 Virus like particles [VLP]
- 2760/18331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18341 Use of virus, viral particle or viral elements as a vector
- 2760/18342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18343 viral genome or elements thereof as genetic vector
- 2760/18344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18345 Special targeting system for viral vectors
- 2760/18351 Methods of production or purification of viral material
- 2760/18352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18361 Methods of inactivation or attenuation
- 2760/18362 by genetic engineering
- 2760/18363 by chemical treatment
- 2760/18364 by serial passage
- 2760/18371 Demonstrated in vivo effect
- 2760/18388 for redistribution
- 2760/18411 . . . Morbillivirus, e.g. Measles virus, canine distemper
- 2760/18421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18423 Virus like particles [VLP]
- 2760/18431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18441 Use of virus, viral particle or viral elements as a vector
- 2760/18442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18443 viral genome or elements thereof as genetic vector
- 2760/18444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18445 Special targeting system for viral vectors
- 2760/18451 Methods of production or purification of viral material
- 2760/18452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18461 Methods of inactivation or attenuation
- 2760/18462 by genetic engineering
- 2760/18463 by chemical treatment
- 2760/18464 by serial passage
- 2760/18471 Demonstrated in vivo effect
- 2760/18488 For redistribution
- 2760/18511 . . . Pneumovirus, e.g. human respiratory syncytial virus
- 2760/18521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18523 Virus like particles [VLP]
- 2760/18531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18541 Use of virus, viral particle or viral elements as a vector
- 2760/18542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18543 viral genome or elements thereof as genetic vector
- 2760/18544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18545 Special targeting system for viral vectors
- 2760/18551 Methods of production or purification of viral material
- 2760/18552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18561 Methods of inactivation or attenuation
- 2760/18562 by genetic engineering
- 2760/18563 by chemical treatment
- 2760/18564 by serial passage
- 2760/18571 Demonstrated in vivo effect
- 2760/18588 for redistribution

- 2760/18611 Respirovirus, e.g. Bovine, human parainfluenza 1,3
- 2760/18621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18623 Virus like particles [VLP]
- 2760/18631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18641 Use of virus, viral particle or viral elements as a vector
- 2760/18642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18643 viral genome or elements thereof as genetic vector
- 2760/18644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18645 Special targeting system for viral vectors
- 2760/18651 Methods of production or purification of viral material
- 2760/18652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18661 Methods of inactivation or attenuation
- 2760/18662 by genetic engineering
- 2760/18663 by chemical treatment
- 2760/18664 by serial passage
- 2760/18671 Demonstrated in vivo effect
- 2760/18688 for redistribution
- 2760/18711 Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- 2760/18721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18723 Virus like particles [VLP]
- 2760/18731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18741 Use of virus, viral particle or viral elements as a vector
- 2760/18742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18743 viral genome or elements thereof as genetic vector
- 2760/18744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18745 Special targeting system for viral vectors
- 2760/18751 Methods of production or purification of viral material
- 2760/18752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18761 Methods of inactivation or attenuation
- 2760/18762 by genetic engineering
- 2760/18763 by chemical treatment
- 2760/18764 by serial passage
- 2760/18771 Demonstrated in vivo effect
- 2760/18788 for redistribution
- 2760/18811 Sendai virus
- 2760/18821 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18822 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18823 Virus like particles [VLP]
- 2760/18831 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18832 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18833 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18834 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18841 Use of virus, viral particle or viral elements as a vector
- 2760/18842 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18843 viral genome or elements thereof as genetic vector
- 2760/18845 Special targeting system for viral vectors
- 2760/18851 Methods of production or purification of viral material
- 2760/18852 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18861 Methods of inactivation or attenuation
- 2760/18862 by genetic engineering
- 2760/18863 by chemical treatment
- 2760/18864 by serial passage
- 2760/18871 Demonstrated in vivo effect
- 2760/18888 for redistribution
- 2760/20011 Rhabdoviridae
- 2760/20021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20023 Virus like particles [VLP]
- 2760/20031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

2760/20034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/20221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/20041	. . .	Use of virus, viral particle or viral elements as a vector	2760/20222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/20042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/20223	Virus like particles [VLP]
2760/20043	viral genome or elements thereof as genetic vector	2760/20231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/20044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/20232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/20045	Special targeting system for viral vectors	2760/20233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20051	. . .	Methods of production or purification of viral material	2760/20234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20052	relating to complementing cells and packaging systems for producing virus or viral particles	2760/20241	Use of virus, viral particle or viral elements as a vector
2760/20061	. . .	Methods of inactivation or attenuation	2760/20242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/20062	by genetic engineering	2760/20243	viral genome or elements thereof as genetic vector
2760/20063	by chemical treatment	2760/20244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/20064	by serial passage	2760/20245	Special targeting system for viral vectors
2760/20071	. . .	Demonstrated <u>in vivo</u> effect	2760/20251	Methods of production or purification of viral material
2760/20088	. . .	for redistribution	2760/20252	relating to complementing cells and packaging systems for producing virus or viral particles
2760/20111	. . .	Lyssavirus, e.g. rabies virus	2760/20261	Methods of inactivation or attenuation
2760/20121	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/20262	by genetic engineering
2760/20122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/20263	by chemical treatment
2760/20123	Virus like particles [VLP]	2760/20264	by serial passage
2760/20131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/20271	Demonstrated <u>in vivo</u> effect
2760/20132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/20288	for redistribution
2760/20133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory			
2760/20134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2770/00		ssRNA viruses positive-sense
2760/20141	Use of virus, viral particle or viral elements as a vector	2770/00011	. . .	Details
2760/20142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2770/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/20143	viral genome or elements thereof as genetic vector	2770/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/20144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/00023	. .	Virus like particles [VLP]
2760/20145	Special targeting system for viral vectors	2770/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/20151	Methods of production or purification of viral material	2770/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/20152	relating to complementing cells and packaging systems for producing virus or viral particles	2770/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20161	Methods of inactivation or attenuation	2770/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20162	by genetic engineering	2770/00041	. .	Use of virus, viral particle or viral elements as a vector
2760/20163	by chemical treatment	2770/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/20164	by serial passage	2770/00043	. . .	viral genome or elements thereof as genetic vector
2760/20171	Demonstrated <u>in vivo</u> effect			
2760/20188	for redistribution			
2760/20211	. . .	Vesiculovirus, e.g. vesicular stomatitis Indiana virus			

- 2770/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/00045 . . . Special targeting system for viral vectors
- 2770/00051 . . . Methods of production or purification of viral material
- 2770/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/00061 . . . Methods of inactivation or attenuation
- 2770/00062 . . . by genetic engineering
- 2770/00063 . . . by chemical treatment
- 2770/00064 . . . by serial passage
- 2770/00071 . . . Demonstrated in vivo effect
- 2770/00088 . . . for redistribution
- 2770/10011 . . . Arteriviridae
- 2770/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/10023 . . . Virus like particles [VLP]
- 2770/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/10043 viral genome or elements thereof as genetic vector
- 2770/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/10045 Special targeting system for viral vectors
- 2770/10051 Methods of production or purification of viral material
- 2770/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/10061 Methods of inactivation or attenuation
- 2770/10062 by genetic engineering
- 2770/10063 by chemical treatment
- 2770/10064 by serial passage
- 2770/10071 Demonstrated in vivo effect
- 2770/10088 for redistribution
- 2770/12011 Astroviridae
- 2770/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/12023 Virus like particles [VLP]
- 2770/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/12041 Use of virus, viral particle or viral elements as a vector
- 2770/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/12043 viral genome or elements thereof as genetic vector
- 2770/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/12045 Special targeting system for viral vectors
- 2770/12051 Methods of production or purification of viral material
- 2770/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/12061 Methods of inactivation or attenuation
- 2770/12062 by genetic engineering
- 2770/12063 by chemical treatment
- 2770/12064 by serial passage
- 2770/12071 Demonstrated in vivo effect
- 2770/12088 for redistribution
- 2770/14011 Bromoviridae
- 2770/14021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/14022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/14023 Virus like particles [VLP]
- 2770/14031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/14032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/14033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/14034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/14041 Use of virus, viral particle or viral elements as a vector
- 2770/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/14043 viral genome or elements thereof as genetic vector
- 2770/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/14045 Special targeting system for viral vectors
- 2770/14051 Methods of production or purification of viral material
- 2770/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/14061 Methods of inactivation or attenuation
- 2770/14062 by genetic engineering
- 2770/14063 by chemical treatment
- 2770/14064 by serial passage
- 2770/14071 Demonstrated in vivo effect

- 2770/14088 . . . for redistribution
- 2770/16011 . . . Caliciviridae
- 2770/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/16023 . . . Virus like particles [VLP]
- 2770/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/16043 viral genome or elements thereof as genetic vector
- 2770/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/16045 Special targeting system for viral vectors
- 2770/16051 Methods of production or purification of viral material
- 2770/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/16061 Methods of inactivation or attenuation
- 2770/16062 by genetic engineering
- 2770/16063 by chemical treatment
- 2770/16064 by serial passage
- 2770/16071 Demonstrated in vivo effect
- 2770/16088 for redistribution
- 2770/18011 . . . Comoviridae
- 2770/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/18023 . . . Virus like particles [VLP]
- 2770/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/18043 viral genome or elements thereof as genetic vector
- 2770/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/18045 Special targeting system for viral vectors
- 2770/18051 Methods of production or purification of viral material
- 2770/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/18061 Methods of inactivation or attenuation
- 2770/18062 by genetic engineering
- 2770/18063 by chemical treatment
- 2770/18064 by serial passage
- 2770/18071 Demonstrated in vivo effect
- 2770/18088 for redistribution
- 2770/20011 . . . Coronaviridae
- 2770/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/20023 . . . Virus like particles [VLP]
- 2770/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/20043 viral genome or elements thereof as genetic vector
- 2770/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/20045 Special targeting system for viral vectors
- 2770/20051 Methods of production or purification of viral material
- 2770/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/20061 Methods of inactivation or attenuation
- 2770/20062 by genetic engineering
- 2770/20063 by chemical treatment
- 2770/20064 by serial passage
- 2770/20071 Demonstrated in vivo effect
- 2770/20088 for redistribution
- 2770/22011 . . . Dicistroviridae
- 2770/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/22023 . . . Virus like particles [VLP]
- 2770/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/22041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/22042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/22043 viral genome or elements thereof as genetic vector
- 2770/22044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/22045 Special targeting system for viral vectors
- 2770/22051 . . . Methods of production or purification of viral material
- 2770/22052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/22061 . . . Methods of inactivation or attenuation
- 2770/22062 by genetic engineering
- 2770/22063 by chemical treatment
- 2770/22064 by serial passage
- 2770/22071 . . . Demonstrated in vivo effect
- 2770/22088 . . . for redistribution
- 2770/24011 . . Flaviviridae
- 2770/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24023 . . . Virus like particles [VLP]
- 2770/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/24042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24043 viral genome or elements thereof as genetic vector
- 2770/24044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24045 Special targeting system for viral vectors
- 2770/24051 . . . Methods of production or purification of viral material
- 2770/24052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24061 . . . Methods of inactivation or attenuation
- 2770/24062 by genetic engineering
- 2770/24063 by chemical treatment
- 2770/24064 by serial passage
- 2770/24071 . . . Demonstrated in vivo effect
- 2770/24088 . . . for redistribution
- 2770/24111 . . . Flavivirus, e.g. yellow fever virus, dengue, JEV
- 2770/24121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24123 Virus like particles [VLP]
- 2770/24131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24141 Use of virus, viral particle or viral elements as a vector
- 2770/24142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24143 viral genome or elements thereof as genetic vector
- 2770/24144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24145 Special targeting system for viral vectors
- 2770/24151 Methods of production or purification of viral material
- 2770/24152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24161 Methods of inactivation or attenuation
- 2770/24162 by genetic engineering
- 2770/24163 by chemical treatment
- 2770/24164 by serial passage
- 2770/24171 Demonstrated in vivo effect
- 2770/24188 for redistribution
- 2770/24211 . . . Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- 2770/24221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24223 Virus like particles [VLP]
- 2770/24231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24241 Use of virus, viral particle or viral elements as a vector
- 2770/24242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24243 viral genome or elements thereof as genetic vector

- 2770/24244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24245 Special targeting system for viral vectors
- 2770/24251 Methods of production or purification of viral material
- 2770/24252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24261 Methods of inactivation or attenuation
- 2770/24262 by genetic engineering
- 2770/24263 by chemical treatment
- 2770/24264 by serial passage
- 2770/24271 Demonstrated in vivo effect
- 2770/24288 for redistribution
- 2770/24311 . . . Pestivirus, e.g. bovine viral diarrhea virus
- 2770/24321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24323 Virus like particles [VLP]
- 2770/24331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24341 Use of virus, viral particle or viral elements as a vector
- 2770/24342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24343 viral genome or elements thereof as genetic vector
- 2770/24344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24345 Special targeting system for viral vectors
- 2770/24351 Methods of production or purification of viral material
- 2770/24352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24361 Methods of inactivation or attenuation
- 2770/24362 by genetic engineering
- 2770/24363 by chemical treatment
- 2770/24364 by serial passage
- 2770/24371 Demonstrated in vivo effect
- 2770/24388 for redistribution
- 2770/26011 . . Flexiviridae
- 2770/26021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/26022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/26023 . . . Virus like particles [VLP]
- 2770/26031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/26032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/26033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/26034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/26041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/26042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/26043 viral genome or elements thereof as genetic vector
- 2770/26044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/26045 Special targeting system for viral vectors
- 2770/26051 . . . Methods of production or purification of viral material
- 2770/26052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/26061 . . . Methods of inactivation or attenuation
- 2770/26062 by genetic engineering
- 2770/26063 by chemical treatment
- 2770/26064 by serial passage
- 2770/26071 . . . Demonstrated in vivo effect
- 2770/26088 . . . for redistribution
- 2770/28011 . . Hepeviridae
- 2770/28021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28023 . . . Virus like particles [VLP]
- 2770/28031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/28042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28043 viral genome or elements thereof as genetic vector
- 2770/28044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28045 Special targeting system for viral vectors
- 2770/28051 . . . Methods of production or purification of viral material
- 2770/28052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28061 . . . Methods of inactivation or attenuation
- 2770/28062 by genetic engineering
- 2770/28063 by chemical treatment
- 2770/28064 by serial passage
- 2770/28071 . . . Demonstrated in vivo effect

- 2770/28088 . . . for redistribution
- 2770/28111 . . . Hepevirus, e.g. hepatitis E virus
- 2770/28121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28123 Virus like particles [VLP]
- 2770/28131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28141 Use of virus, viral particle or viral elements as a vector
- 2770/28142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28143 viral genome or elements thereof as genetic vector
- 2770/28144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28145 Special targeting system for viral vectors
- 2770/28151 Methods of production or purification of viral material
- 2770/28152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28161 Methods of inactivation or attenuation
- 2770/28162 by genetic engineering
- 2770/28163 by chemical treatment
- 2770/28164 by serial passage
- 2770/28171 Demonstrated in vivo effect
- 2770/28188 for redistribution
- 2770/30011 . . . Nodaviridae
- 2770/30021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/30022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/30023 Virus like particles [VLP]
- 2770/30031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/30032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/30033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/30034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/30041 Use of virus, viral particle or viral elements as a vector
- 2770/30042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/30043 viral genome or elements thereof as genetic vector
- 2770/30044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/30045 Special targeting system for viral vectors
- 2770/30051 Methods of production or purification of viral material
- 2770/30052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/30061 Methods of inactivation or attenuation
- 2770/30062 by genetic engineering
- 2770/30063 by chemical treatment
- 2770/30064 by serial passage
- 2770/30071 Demonstrated in vivo effect
- 2770/30088 for redistribution
- 2770/32011 . . . Picornaviridae
- 2770/32021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32023 Virus like particles [VLP]
- 2770/32031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32041 Use of virus, viral particle or viral elements as a vector
- 2770/32042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32043 viral genome or elements thereof as genetic vector
- 2770/32044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32045 Special targeting system for viral vectors
- 2770/32051 Methods of production or purification of viral material
- 2770/32052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32061 Methods of inactivation or attenuation
- 2770/32062 by genetic engineering
- 2770/32063 by chemical treatment
- 2770/32064 by serial passage
- 2770/32071 Demonstrated in vivo effect
- 2770/32088 for redistribution
- 2770/32111 Aphthovirus, e.g. footandmouth disease virus
- 2770/32121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32123 Virus like particles [VLP]
- 2770/32131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/32133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32141 Use of virus, viral particle or viral elements as a vector
- 2770/32142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32143 viral genome or elements thereof as genetic vector
- 2770/32144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32145 Special targeting system for viral vectors
- 2770/32151 Methods of production or purification of viral material
- 2770/32152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32161 Methods of inactivation or attenuation
- 2770/32162 by genetic engineering
- 2770/32163 by chemical treatment
- 2770/32164 by serial passage
- 2770/32171 Demonstrated *in vivo* effect
- 2770/32188 for redistribution
- 2770/32211 Cardiovirus, e.g. encephalomyocarditis virus
- 2770/32221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32223 Virus like particles [VLP]
- 2770/32231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32241 Use of virus, viral particle or viral elements as a vector
- 2770/32242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32243 viral genome or elements thereof as genetic vector
- 2770/32244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32245 Special targeting system for viral vectors
- 2770/32251 Methods of production or purification of viral material
- 2770/32252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32261 Methods of inactivation or attenuation
- 2770/32262 by genetic engineering
- 2770/32263 by chemical treatment
- 2770/32264 by serial passage
- 2770/32271 Demonstrated *in vivo* effect
- 2770/32288 for redistribution
- 2770/32311 Enterovirus
- 2770/32321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32323 Virus like particles [VLP]
- 2770/32331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32341 Use of virus, viral particle or viral elements as a vector
- 2770/32342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32343 viral genome or elements thereof as genetic vector
- 2770/32344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32345 Special targeting system for viral vectors
- 2770/32351 Methods of production or purification of viral material
- 2770/32352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32361 Methods of inactivation or attenuation
- 2770/32362 by genetic engineering
- 2770/32363 by chemical treatment
- 2770/32364 by serial passage
- 2770/32371 Demonstrated *in vivo* effect
- 2770/32388 for redistribution
- 2770/32411 Hepatovirus, i.e. hepatitis A virus
- 2770/32421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32423 Virus like particles [VLP]
- 2770/32431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32441 Use of virus, viral particle or viral elements as a vector
- 2770/32442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32443 viral genome or elements thereof as genetic vector

- 2770/32444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32445 Special targeting system for viral vectors
- 2770/32451 Methods of production or purification of viral material
- 2770/32452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32461 Methods of inactivation or attenuation
- 2770/32462 by genetic engineering
- 2770/32463 by chemical treatment
- 2770/32464 by serial passage
- 2770/32471 Demonstrated in vivo effect
- 2770/32488 for redistribution
- 2770/32511 . . . Parechovirus, e.g. human parechovirus
- 2770/32521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32523 Virus like particles [VLP]
- 2770/32531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32541 Use of virus, viral particle or viral elements as a vector
- 2770/32542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32543 viral genome or elements thereof as genetic vector
- 2770/32544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32545 Special targeting system for viral vectors
- 2770/32551 Methods of production or purification of viral material
- 2770/32552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32561 Methods of inactivation or attenuation
- 2770/32562 by genetic engineering
- 2770/32563 by chemical treatment
- 2770/32564 by serial passage
- 2770/32571 Demonstrated in vivo effect
- 2770/32588 for redistribution
- 2770/32611 . . . Poliovirus
- 2770/32621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32623 Virus like particles [VLP]
- 2770/32631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32641 Use of virus, viral particle or viral elements as a vector
- 2770/32642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32643 viral genome or elements thereof as genetic vector
- 2770/32644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32645 Special targeting system for viral vectors
- 2770/32651 Methods of production or purification of viral material
- 2770/32652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32661 Methods of inactivation or attenuation
- 2770/32662 by genetic engineering
- 2770/32663 by chemical treatment
- 2770/32664 by serial passage
- 2770/32671 Demonstrated in vivo effect
- 2770/32688 for redistribution
- 2770/32711 . . . Rhinovirus
- 2770/32721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32723 Virus like particles [VLP]
- 2770/32731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32741 Use of virus, viral particle or viral elements as a vector
- 2770/32742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32743 viral genome or elements thereof as genetic vector
- 2770/32744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32745 Special targeting system for viral vectors
- 2770/32751 Methods of production or purification of viral material
- 2770/32752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32761 Methods of inactivation or attenuation
- 2770/32762 by genetic engineering
- 2770/32763 by chemical treatment
- 2770/32764 by serial passage
- 2770/32771 Demonstrated in vivo effect

- 2770/32788 for redistribution
- 2770/34011 . . Potyviridae
- 2770/34021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/34022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/34023 . . . Virus like particles [VLP]
- 2770/34031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/34032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/34033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/34034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/34041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/34042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/34043 viral genome or elements thereof as genetic vector
- 2770/34044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/34045 Special targeting system for viral vectors
- 2770/34051 . . . Methods of production or purification of viral material
- 2770/34052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/34061 . . . Methods of inactivation or attenuation
- 2770/34062 by genetic engineering
- 2770/34063 by chemical treatment
- 2770/34064 by serial passage
- 2770/34071 . . . Demonstrated in vivo effect
- 2770/34088 . . . for redistribution
- 2770/36011 . . Togaviridae
- 2770/36021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36023 . . . Virus like particles [VLP]
- 2770/36031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/36042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36043 viral genome or elements thereof as genetic vector
- 2770/36044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36045 Special targeting system for viral vectors
- 2770/36051 . . . Methods of production or purification of viral material
- 2770/36052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36061 . . . Methods of inactivation or attenuation
- 2770/36062 by genetic engineering
- 2770/36063 by chemical treatment
- 2770/36064 by serial passage
- 2770/36071 . . . Demonstrated in vivo effect
- 2770/36088 . . . for redistribution
- 2770/36111 . . . Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- 2770/36121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36123 Virus like particles [VLP]
- 2770/36131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36141 Use of virus, viral particle or viral elements as a vector
- 2770/36142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36143 viral genome or elements thereof as genetic vector
- 2770/36144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36145 Special targeting system for viral vectors
- 2770/36151 Methods of production or purification of viral material
- 2770/36152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36161 Methods of inactivation or attenuation
- 2770/36162 by genetic engineering
- 2770/36163 by chemical treatment
- 2770/36164 by serial passage
- 2770/36171 Demonstrated in vivo effect
- 2770/36188 for redistribution
- 2770/36211 . . . Rubivirus, e.g. rubella virus
- 2770/36221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36223 Virus like particles [VLP]
- 2770/36231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2770/36232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36241 Use of virus, viral particle or viral elements as a vector
- 2770/36242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36243 viral genome or elements thereof as genetic vector
- 2770/36244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36245 Special targeting system for viral vectors
- 2770/36251 Methods of production or purification of viral material
- 2770/36252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36261 Methods of inactivation or attenuation
- 2770/36262 by genetic engineering
- 2770/36263 by chemical treatment
- 2770/36264 by serial passage
- 2770/36271 Demonstrated in vivo effect
- 2770/36288 for redistribution
- 2770/38011 Tombusviridae
- 2770/38021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/38022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/38023 Virus like particles [VLP]
- 2770/38031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/38032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/38033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/38034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/38041 Use of virus, viral particle or viral elements as a vector
- 2770/38042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/38043 viral genome or elements thereof as genetic vector
- 2770/38044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/38045 Special targeting system for viral vectors
- 2770/38051 Methods of production or purification of viral material
- 2770/38052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/38061 Methods of inactivation or attenuation
- 2770/38062 by genetic engineering
- 2770/38063 by chemical treatment
- 2770/38064 by serial passage
- 2770/38071 Demonstrated in vivo effect
- 2770/38088 for redistribution
- 2770/40011 Tymoviridae
- 2770/40021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/40022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/40023 Virus like particles [VLP]
- 2770/40031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/40032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/40033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/40034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/40041 Use of virus, viral particle or viral elements as a vector
- 2770/40042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/40043 viral genome or elements thereof as genetic vector
- 2770/40044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/40045 Special targeting system for viral vectors
- 2770/40051 Methods of production or purification of viral material
- 2770/40052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/40061 Methods of inactivation or attenuation
- 2770/40062 by genetic engineering
- 2770/40063 by chemical treatment
- 2770/40064 by serial passage
- 2770/40071 Demonstrated in vivo effect
- 2770/40088 for redistribution
- 2780/00** **Naked RNA viruses**
- 2780/00011 Details
- 2780/00021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/00022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/00023 Virus like particles [VLP]
- 2780/00031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/00032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/00033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/00034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/00041 Use of virus, viral particle or viral elements as a vector
- 2780/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule

- 2780/00043 . . . viral genome or elements thereof as genetic vector
- 2780/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045 . . . Special targeting system for viral vectors
- 2780/00051 . . Methods of production or purification of viral material
- 2780/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061 . . Methods of inactivation or attenuation
- 2780/00062 . . . by genetic engineering
- 2780/00063 . . . by chemical treatment
- 2780/00064 . . . by serial passage
- 2780/00071 . . Demonstrated in vivo effect
- 2780/00088 . . for redistribution
- 2780/10011 . . Narnaviridae
- 2780/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/10023 . . . Virus like particles [VLP]
- 2780/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2780/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/10043 viral genome or elements thereof as genetic vector
- 2780/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/10045 Special targeting system for viral vectors
- 2780/10051 . . . Methods of production or purification of viral material
- 2780/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/10061 . . . Methods of inactivation or attenuation
- 2780/10062 by genetic engineering
- 2780/10063 by chemical treatment
- 2780/10064 by serial passage
- 2780/10071 . . . Demonstrated in vivo effect
- 2780/10088 . . . for redistribution
- 2790/00** **Viroids or subviral agents**
- 2790/00011 . Details
- 2790/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/00023 . . Virus like particles [VLP]
- 2790/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/00041 . . Use of virus, viral particle or viral elements as a vector
- 2790/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/00043 viral genome or elements thereof as genetic vector
- 2790/00044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/00045 Special targeting system for viral vectors
- 2790/00051 . . . Methods of production or purification of viral material
- 2790/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/00061 . . . Methods of inactivation or attenuation
- 2790/00062 by genetic engineering
- 2790/00063 by chemical treatment
- 2790/00064 by serial passage
- 2790/00071 . . Demonstrated in vivo effect
- 2790/00088 . . for redistribution
- 2790/10011 . . Prions
- 2790/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/10023 . . . Virus like particles [VLP]
- 2790/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/10043 viral genome or elements thereof as genetic vector
- 2790/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/10045 Special targeting system for viral vectors
- 2790/10051 . . . Methods of production or purification of viral material
- 2790/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/10061 . . . Methods of inactivation or attenuation
- 2790/10062 by genetic engineering

- 2790/10063 by chemical treatment
- 2790/10064 by serial passage
- 2790/10071 . . . Demonstrated in vivo effect
- 2790/10088 . . . for redistribution
- 2790/12011 . . Satellite viruses
- 2790/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/12023 . . . Virus like particles [VLP]
- 2790/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/12043 viral genome or elements thereof as genetic vector
- 2790/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/12045 Special targeting system for viral vectors
- 2790/12051 . . . Methods of production or purification of viral material
- 2790/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/12061 . . . Methods of inactivation or attenuation
- 2790/12062 by genetic engineering
- 2790/12063 by chemical treatment
- 2790/12064 by serial passage
- 2790/12071 . . . Demonstrated in vivo effect
- 2790/12088 . . . for redistribution
- 2790/14011 . . Viroids
- 2790/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/14023 . . . Virus like particles [VLP]
- 2790/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/14043 viral genome or elements thereof as genetic vector
- 2790/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/14045 Special targeting system for viral vectors
- 2790/14051 . . . Methods of production or purification of viral material
- 2790/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/14061 . . . Methods of inactivation or attenuation
- 2790/14062 by genetic engineering
- 2790/14063 by chemical treatment
- 2790/14064 by serial passage
- 2790/14071 . . . Demonstrated in vivo effect
- 2790/14088 . . . for redistribution
- 2792/00 Archaeobacteria viruses**
- 2792/00011 . Details
- 2792/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/00023 . . Virus like particles [VLP]
- 2792/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/00041 . . Use of virus, viral particle or viral elements as a vector
- 2792/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/00043 . . . viral genome or elements thereof as genetic vector
- 2792/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/00045 . . . Special targeting system for viral vectors
- 2792/00051 . . Methods of production or purification of viral material
- 2792/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/00061 . . Methods of inactivation or attenuation
- 2792/00062 . . . by genetic engineering
- 2792/00063 . . . by chemical treatment
- 2792/00064 . . . by serial passage
- 2792/00071 . . Demonstrated in vivo effect
- 2792/00088 . . for redistribution
- 2792/10011 . . Fuselloviridae
- 2792/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/10023 . . . Virus like particles [VLP]

- 2792/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/10043 viral genome or elements thereof as genetic vector
- 2792/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/10045 Special targeting system for viral vectors
- 2792/10051 . . . Methods of production or purification of viral material
- 2792/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/10061 . . . Methods of inactivation or attenuation
- 2792/10062 by genetic engineering
- 2792/10063 by chemical treatment
- 2792/10064 by serial passage
- 2792/10071 . . . Demonstrated in vivo effect
- 2792/10088 . . . for redistribution
- 2792/12011 . . Guttaviridae
- 2792/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/12023 . . . Virus like particles [VLP]
- 2792/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/12043 viral genome or elements thereof as genetic vector
- 2792/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/12045 Special targeting system for viral vectors
- 2792/12051 . . . Methods of production or purification of viral material
- 2792/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/12061 . . . Methods of inactivation or attenuation
- 2792/12062 by genetic engineering
- 2792/12063 by chemical treatment
- 2792/12064 by serial passage
- 2792/12071 . . . Demonstrated in vivo effect
- 2792/12088 . . . for redistribution
- 2795/00 Bacteriophages**
- 2795/00011 . Details
- 2795/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/00023 . . Virus like particles [VLP]
- 2795/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/00041 . . Use of virus, viral particle or viral elements as a vector
- 2795/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/00043 . . . viral genome or elements thereof as genetic vector
- 2795/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/00045 . . . Special targeting system for viral vectors
- 2795/00051 . . Methods of production or purification of viral material
- 2795/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/00061 . . Methods of inactivation or attenuation
- 2795/00062 . . . by genetic engineering
- 2795/00063 . . . by chemical treatment
- 2795/00064 . . . by serial passage
- 2795/00071 . . Demonstrated in vivo effect
- 2795/00088 . . for redistribution
- 2795/10011 . . dsDNA Bacteriophages
- 2795/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10023 . . . Virus like particles [VLP]
- 2795/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10041 . . . Use of virus, viral particle or viral elements as a vector

- 2795/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10043 viral genome or elements thereof as genetic vector
- 2795/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10045 Special targeting system for viral vectors
- 2795/10051 Methods of production or purification of viral material
- 2795/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10061 Methods of inactivation or attenuation
- 2795/10062 by genetic engineering
- 2795/10063 by chemical treatment
- 2795/10064 by serial passage
- 2795/10071 Demonstrated *in vivo* effect
- 2795/10088 for redistribution
- 2795/10111 Myoviridae
- 2795/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10123 Virus like particles [VLP]
- 2795/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10141 Use of virus, viral particle or viral elements as a vector
- 2795/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10143 viral genome or elements thereof as genetic vector
- 2795/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10145 Special targeting system for viral vectors
- 2795/10151 Methods of production or purification of viral material
- 2795/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10161 Methods of inactivation or attenuation
- 2795/10162 by genetic engineering
- 2795/10163 by chemical treatment
- 2795/10164 by serial passage
- 2795/10171 Demonstrated *in vivo* effect
- 2795/10188 for redistribution
- 2795/10211 Podoviridae
- 2795/10221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10223 Virus like particles [VLP]
- 2795/10231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10241 Use of virus, viral particle or viral elements as a vector
- 2795/10242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10243 viral genome or elements thereof as genetic vector
- 2795/10244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10245 Special targeting system for viral vectors
- 2795/10251 Methods of production or purification of viral material
- 2795/10252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10261 Methods of inactivation or attenuation
- 2795/10262 by genetic engineering
- 2795/10263 by chemical treatment
- 2795/10264 by serial passage
- 2795/10271 Demonstrated *in vivo* effect
- 2795/10288 for redistribution
- 2795/10311 Siphoviridae
- 2795/10321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10323 Virus like particles [VLP]
- 2795/10331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10341 Use of virus, viral particle or viral elements as a vector
- 2795/10342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10343 viral genome or elements thereof as genetic vector
- 2795/10344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10345 Special targeting system for viral vectors
- 2795/10351 Methods of production or purification of viral material
- 2795/10352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10361 Methods of inactivation or attenuation

- 2795/10362 by genetic engineering
- 2795/10363 by chemical treatment
- 2795/10364 by serial passage
- 2795/10371 Demonstrated in vivo effect
- 2795/10388 for redistribution
- 2795/12011 . . dsRNA Bacteriophages
- 2795/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/12023 . . . Virus like particles [VLP]
- 2795/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/12043 viral genome or elements thereof as genetic vector
- 2795/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/12045 Special targeting system for viral vectors
- 2795/12051 . . . Methods of production or purification of viral material
- 2795/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/12061 . . . Methods of inactivation or attenuation
- 2795/12062 by genetic engineering
- 2795/12063 by chemical treatment
- 2795/12064 by serial passage
- 2795/12071 . . . Demonstrated in vivo effect
- 2795/12088 . . . for redistribution
- 2795/14011 . . ssDNA Bacteriophages
- 2795/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14023 . . . Virus like particles [VLP]
- 2795/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14043 viral genome or elements thereof as genetic vector
- 2795/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14045 Special targeting system for viral vectors
- 2795/14051 . . . Methods of production or purification of viral material
- 2795/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14061 . . . Methods of inactivation or attenuation
- 2795/14062 by genetic engineering
- 2795/14063 by chemical treatment
- 2795/14064 by serial passage
- 2795/14071 . . . Demonstrated in vivo effect
- 2795/14088 . . . for redistribution
- 2795/14111 . . . Inoviridae
- 2795/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14123 Virus like particles [VLP]
- 2795/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14141 Use of virus, viral particle or viral elements as a vector
- 2795/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14143 viral genome or elements thereof as genetic vector
- 2795/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14145 Special targeting system for viral vectors
- 2795/14151 Methods of production or purification of viral material
- 2795/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14161 Methods of inactivation or attenuation
- 2795/14162 by genetic engineering
- 2795/14163 by chemical treatment
- 2795/14164 by serial passage
- 2795/14171 Demonstrated in vivo effect
- 2795/14188 for redistribution
- 2795/14211 . . . Microviridae
- 2795/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14223 Virus like particles [VLP]
- 2795/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2795/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14241 Use of virus, viral particle or viral elements as a vector
- 2795/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14243 viral genome or elements thereof as genetic vector
- 2795/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14245 Special targeting system for viral vectors
- 2795/14251 Methods of production or purification of viral material
- 2795/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14261 Methods of inactivation or attenuation
- 2795/14262 by genetic engineering
- 2795/14263 by chemical treatment
- 2795/14264 by serial passage
- 2795/14271 Demonstrated *in vivo* effect
- 2795/14288 for redistribution
- 2795/16011 . . ssRNA Bacteriophages negative-sense
- 2795/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/16023 . . . Virus like particles [VLP]
- 2795/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/16043 viral genome or elements thereof as genetic vector
- 2795/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/16045 Special targeting system for viral vectors
- 2795/16051 . . . Methods of production or purification of viral material
- 2795/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/16061 . . . Methods of inactivation or attenuation
- 2795/16062 by genetic engineering
- 2795/16063 by chemical treatment
- 2795/16064 by serial passage
- 2795/16071 . . . Demonstrated *in vivo* effect
- 2795/16088 . . . for redistribution
- 2795/18011 . . ssRNA Bacteriophages positive-sense
- 2795/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18023 . . . Virus like particles [VLP]
- 2795/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18043 viral genome or elements thereof as genetic vector
- 2795/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/18045 Special targeting system for viral vectors
- 2795/18051 . . . Methods of production or purification of viral material
- 2795/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/18061 . . . Methods of inactivation or attenuation
- 2795/18062 by genetic engineering
- 2795/18063 by chemical treatment
- 2795/18064 by serial passage
- 2795/18071 . . . Demonstrated *in vivo* effect
- 2795/18088 . . . for redistribution
- 2795/18111 . . . Leviviridae
- 2795/18121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18123 Virus like particles [VLP]
- 2795/18131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/18133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18141 Use of virus, viral particle or viral elements as a vector
- 2795/18142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18143 viral genome or elements thereof as genetic vector

2795/18144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/18145	Special targeting system for viral vectors
2795/18151	Methods of production or purification of viral material
2795/18152	relating to complementing cells and packaging systems for producing virus or viral particles
2795/18161	Methods of inactivation or attenuation
2795/18162	by genetic engineering
2795/18163	by chemical treatment
2795/18164	by serial passage
2795/18171	Demonstrated <i>in vivo</i> effect
2795/18188	for redistribution
2796/00		Viruses not covered by groups
		C12N 2710/00 - C12N 2795/00
2799/00		Uses of viruses
		WARNING
		From March 15, 2012 codes in the range C12N 2799/00 - C12N 2799/06 are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in C12N 2710/00-C12N 2795/00
2799/02	as vector
2799/021	for the expression of a heterologous nucleic acid
2799/022	where the vector is derived from an adenovirus
2799/023	where the vector is derived from a poxvirus
2799/025	where the vector is derived from a parvovirus
2799/026	where the vector is derived from a baculovirus
2799/027	where the vector is derived from a retrovirus
2799/028	where the vector is derived from a herpesvirus
2799/04	<i>in vivo</i>
2799/06	<i>in vitro</i>
2800/00		Nucleic acids vectors
2800/10	Plasmid DNA
2800/101	for bacteria
2800/102	for yeast
2800/103	for invertebrates
2800/105	for insects
2800/106	for vertebrates
2800/107	for mammalian
2800/108	episomal vectors
2800/20	Pseudochromosomes, minichromosomes
2800/202	of bacteriophage origin
2800/204	of bacterial origin, e.g. BAC
2800/206	of yeast origin, e.g. YAC, 2u
2800/208	of mammalian origin, e.g. minichromosome
2800/22	Vectors comprising a coding region that has been codon optimised for expression in a respective host
2800/24	Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
2800/30	Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
2800/40	Systems of functionally co-operating vectors
2800/50	Vectors for producing vectors
2800/60	Vectors containing traps for, e.g. exons, promoters
2800/70	Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
2800/80	Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
2800/90	Vectors containing a transposable element
2800/95	Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
2810/00		Vectors comprising a targeting moiety
2810/10	Vectors comprising a non-peptidic targeting moiety
2810/40	Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
2810/405	Vectors comprising RGD peptide
2810/50	Vectors comprising as targeting moiety peptide derived from defined protein
2810/55	from bacteria
2810/60	from viruses
2810/6009	dsDNA viruses
2810/6018	Adenoviridae
2810/6027	ssDNA viruses
2810/6036	DNA rev transcr viruses
2810/6045	RNA rev transcr viruses
2810/6054	Retroviridae
2810/6063	ds RNA viruses
2810/6072	negative strand RNA viruses
2810/6081	rhabdoviridae, e.g. VSV
2810/609	positive strand RNA viruses
2810/65	from plants
2810/70	from fungi
2810/75	from invertebrates
2810/80	from vertebrates
2810/85	mammalian
2810/851	from growth factors; from growth regulators
2810/852	from cytokines; from lymphokines; from interferons
2810/853	from tumor necrosis factor, TNF
2810/854	from hormones
2810/855	from receptors; from cell surface antigens; from cell surface determinants
2810/856	from integrins
2810/857	from blood coagulation or fibrinolysis factors
2810/858	from apolipoproteins
2810/859	from immunoglobulins
2810/90	avian
2820/00		Vectors comprising a special origin of replication system
2820/002	inducible or controllable
2820/005	cell-cycle regulated
2820/007	tissue or cell-specific
2820/10	multiple origins of replication
2820/55	from bacteria
2820/60	from viruses
2820/65	from plants
2820/70	from fungi
2820/702	yeast
2820/704	<i>S. cerevisiae</i>
2820/706	<i>S. pombe</i>
2820/708	<i>C. albicans</i>
2820/75	from invertebrates
2820/80	from vertebrates
2820/85	mammalian

2820/90	. . avian
2830/00	Vector systems having a special element relevant for transcription
2830/001	. controllable enhancer/promoter combination
2830/002	. . inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
2830/003	. . . tet inducible
2830/005	. . repressible enhancer/promoter combination, e.g. KRAB
2830/006	. . . tet repressible
2830/007	. cell cycle specific enhancer/promoter combination
2830/008	. cell type or tissue specific enhancer/promoter combination
2830/15	. chimeric enhancer/promoter combination
2830/20	. transcription of more than one cistron
2830/205	. . bidirectional
2830/30	. being an enhancer not forming part of the promoter region
2830/32	. being an silencer not forming part of the promoter region
2830/34	. being a transcription initiation element
2830/36	. being a transcription termination element
2830/38	. being a stuffer
2830/40	. being an insulator
2830/42	. being an intron or intervening sequence for splicing and/or stability of RNA
2830/46	. elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
2830/48	. regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
2830/50	. regulating RNA stability, not being an intron, e.g. poly A signal
2830/52	. encoding ribozyme for self-inactivation
2830/55	. from bacteria
2830/60	. from viruses
2830/65	. from plants
2830/70	. from fungi
2830/702	. . yeast
2830/704	. . . S. cerevisiae
2830/706	. . . S. pombe
2830/708	. . . C. albicans
2830/75	. from invertebrates
2830/80	. from vertebrates
2830/85	. . mammalian
2830/90	. . avian
2840/00	Vectors comprising a special translation-regulating system
2840/002	. controllable or inducible
2840/005	. cell cycle specific
2840/007	. cell or tissue specific
2840/10	. regulates levels of translation
2840/102	. . inhibiting translation
2840/105	. . enhancing translation
2840/107	. . inhibiting translational read-through
2840/20	. translation of more than one cistron
2840/203	. . having an IRES
2840/206	. . . having multiple IRES
2840/44	. being a specific part of the splice mechanism, e.g. donor, acceptor

2840/445	. . for trans-splicing, e.g. polypyrimidine tract, branch point splicing
2840/50	. utilisation of non-ATG initiation codon

NOTE

This groups covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here

2840/55	. from bacteria
2840/60	. from viruses
2840/65	. from plants
2840/70	. from fungi
2840/702	. . yeast
2840/704	. . . S. cerevisiae
2840/706	. . . S. pombe
2840/708	. . . C. albicans
2840/75	. from invertebrates
2840/80	. from vertebrates
2840/85	. . mammalian
2840/90	. . avian

2999/00 Further aspects of viruses or vectors not covered by groups [C12N 2710/00](#) - [C12N 2796/00](#) or [C12N 2800/00](#)

NOTES

1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

2999/002	. Adverse teaching
2999/005	. Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
2999/007	. Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals